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ABSTRACT  
Probiotics are live microorganisms that can confer health benefits to the host. 
They have long been consumed through fermented foods. While the specific mechanisms 
of probiotics are largely unclear, there is evidence that their beneficial effects may be 
attributed to the microbes’ ability to modify the gastrointestinal (GI) environment, to 
modulate host immune response, or to produce natural products that directly inhibit 
pathogens in the gut. With the increasing awareness of the important functions that the 
gut microbiota plays in affecting host heath, probiotics may no longer just stay as simple 
dietary supplements, but become a promising approach to disease management.  
With recent advances in synthetic biology, novel functions can be introduced into 
these “good” microbes to provide additional benefits. Genetically engineered bacteria 
have been developed to specifically target pathogens or effectively deliver therapeutics to 
the GI tract. However, there are significant limitations to the existing systems developed. 
For example, the engineered pathogen sensors largely rely on the similarity between the 
host and the pathogens, the therapeutics delivery systems are usually constrained by the 
molecular structures, and the majority of the works have been limited to laboratory 
settings.  
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In this dissertation, I present a system we have developed based on a food-grade 
probiotic, Lactococcus lactis, and demonstrate a synthetic biology methodology that 
could be applied to build biosensors of other pathogens or environmental signals, as well 
as a generalizable peptide delivery vehicle to the GI tract. I will present my work in three 
parts. (1) The discovery of an effective antagonistic effect of L. lactis against the 
infectious diarrheal disease cholera, and elucidation of the mechanism with an infant 
mouse model. (2) The development of a diagnostic circuit in L. lacits that enables in situ 
detection of the pathogen and easy readout through fecal sample analysis. (3) The design 
of a generalizable therapeutic peptide delivery system utilizing the endogenous secretion 
pathway of L. lacits. Overall, my work exploits the natural and engineered benefits of the 
probiotic L. lactis and demonstrates its use in the intestinal disease diagnosis and therapy. 
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CHAPTER ONE: INTRODUCTION 
Gastrointestinal (GI) diseases impose a heavy burden on global health (Vos et al., 
2015). In developed countries, there are major concerns regarding the large numbers of 
hospitalizations and associated costs for patients with chronic GI disorders (Peery et al., 
2015). In the United States, the hospital admissions due to Clostridium difficile infection 
increased by 150% from 2003 to 2013. The duration and cost of hospitalization due to 
inflammatory bowel diseases (IBD) are also on the rise. Other than infection and 
inflammation, another serious concern is colorectal cancer. Colorectal cancer is the 
leading cause of death among GI disorders in the United States. There were more than 1 
million people living with diagnosed colorectal cancer as of 2011, and an estimate of 
136,830 new cases each year (Peery et al., 2015). In regions with low resources and 
under-developed infrastructure, significant numbers of GI infections and diarrheal 
diseases are also observed (Kirk et al., 2015). A study of global health data in 2010 found 
that the 22 most prevalent GI infectious diseases contributed to 1.09 million deaths, 
among which 34% were children under 5 years old. The pathogens responsible for most 
deaths are norovirus, enteropathogenic Escherichia coli (EPEC), Vibrio cholerae, and 
Shigella spp. (Kirk et al., 2015). Although the global incidents of GI infections and 
diarrheal diseases are declining, the high mortality and morbidity rates in specific regions 
are far from negligible. Furthermore, with rapidly spreading antibiotic resistance (WHO, 
2016), bacterial infections are returning as a concerning global issue. Overall, be it acute 
and chronic infections, inflammations, or cancer, traditional medical solutions are not 
effectively improving the situation facing patients with GI disorders. Therefore, we will 
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need to explore more innovative tools and methods to tackle these challenges.  
Significant knowledge and technological advancements in microbiology and 
genomic analysis have enabled an emerging field of microbiome research and provided 
new insight toward more effective management of GI disorders. In the following sections, 
I will first give an overview of the important roles that the gut microbiota play in human 
health and how these discoveries have revived the long-existing interest in the benefits of 
probiotics. Following that, I will introduce how genetic engineering and synthetic biology 
techniques can add novel functions to the microbiota and allow for designing smart 
therapies or smart living diagnostics. Finally, I will narrow the scope to one particular 
probiotic bacterium, Lactococcus lactis, as the major focus of study and a representative 
for probiotic tool development. 
 
1.1 Gut Microbiota and Probiotics 
There has been ever-increasing awareness of the important and versatile functions 
the gut microbiota plays in determining the health status of the host. The most 
straightforward effect is that host-microbe interactions shape the nutrient environment of 
the intestines and thereby, the nutrition and metabolism profile of the host (Hooper, 
Midtvedt, & Gordon, 2002; Nicholson et al., 2012). Gut microbiota also modulate the 
host immune response through direct and metabolite-dependent interactions (Rooks & 
Garrett, 2016; Smith et al., 2013). Strikingly, the gut microbiota can also affect the 
central nervous system and brain function through chemical communications (the “gut-
brain axis”). Alterations in microbiota may have consequences for behavior and mental 
states, such as anxiety and depression (Cryan & O’Mahony, 2011; Foster & McVey 
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Neufeld, 2013). There is also evidence that commensal gut bacteria have the ability to 
restrict or promote pathogen growth through mechanisms that often involve metabolic 
interactions or the modulation of host immune responses (Bäumler & Sperandio, 2016; 
Fukuda et al., 2011; Kamada, Chen, Inohara, & Núñez, 2013; Liévin-Le Moal & Servin, 
2014). Microbiota also plays a role in clearing the pathogens in Salmonella infections, 
which is independent of the secreted IgA (Endt et al., 2010). 
Microbiota interventions have been utilized to treat or alleviate a variety of 
gastrointestinal disorders (Kamada et al., 2013; Marteau, de Vrese, Cellier, & 
Schrezenmeir, 2001). Common therapeutic methods can be placed in three categories: 
molecular based, microbe-based, and ecology-remodeling methods (Holmes et al., 2012; 
Sheth, Cabral, Chen, & Wang, 2016). Molecular drugs are the most traditionally used 
means, to eradicate species (e.g. antibiotics) or target specific microbial genes (e.g. toxins 
or colonization factors). The use of microbe-based therapies is relatively new, but the 
concept has existed for centuries, as in the use of probiotics to promote health. The 
potential use of bacteriophage to modify the microbiota also belongs to this category 
(Krom, Bhargava, Lobritz, & Collins, 2015; Yen et al., 2017), wherein natural or 
engineered bacteriophages are delivered to the gut and specifically target a pathogenic 
species. A more rigorous approach, the transferal of the entire microbiota from a healthy 
individual to a patient (fecal transplant) aims to alter the microbial ecology in the gut. 
Though still at a relatively early stage and facing many scientific and regulatory 
challenges, fecal transplant has made significant advances in treating recurring C. diff-
associated colitis, and IBD (Colman & Rubin, 2014; Weingarden et al., 2015). 
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Figure 1. The scale and specificity of various microbiome-modulating strategies. 
Orange bubbles are molecular-based; green bubbles are microbe-based methods; blue bubbles are 
ecology-remodeling methods. (Figure from adapted from Sheth et al., 2016.) 
 
Probiotics are live, consumable microorganisms that can promote health in the host. 
As one of the microbiota-modulating strategies, the benefits of probiotics have been 
recognized for centuries. The idea that seeding the gut with “good” microbes could 
improve health has reemerged in the early 20th century (Marteau et al., 2001). There is 
evidence that certain probiotic bacteria can enhance our immune system, modulate 
inflammation, reduce diarrhea duration, and fight pathogenic microbes (Drisko, Giles, & 
Bischoff, 2003; Kopp-Hoolihan, 2001; Michail, Sylvester, Fuchs, & Issenman, 2006). 
Though most of the mechanisms of probiotics’ beneficial effect have not been fully 
understood, the general hypothesis is that they mainly work through altering the physical 
chemical environment of the gut microflora and interacting with the host’s immune 
system. A major group among the probiotics family is the lactic acid bacteria (LAB). 
They are labeled “generally recognized as safe (GRAS)” for human consumption, as live 
LAB strains are commonly found in fermented dairy products and other food 
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supplements for human consumption. A few examples of clinically verified health 
benefits brought by orally administered probiotics (including bacteria and yeast) are 
summarized in Table 1. 
LAB Strain Benefits Sample Size 
Lactobacillus plantarum 
(w/ fructooligosaccharide) 
Prevent neonatal sepsis 4556 infants a 
Lactobacillus rhamnosus GG 
Shorten duration of acute diarrhea 
caused by rotavirus 
287 children b 
Lactobacillus casei Shirota 
Improve triple-antibiotic-therapy-
induced eradication of Helicobactor 
pylori 
85 adults b 
Lactobacillus acidophilus 
and Bifidobacterium infantis 
Reduce the incidence and severity  of 
necrotizing enterocolitis 
367 very-low-birth-
weight infants c 
Bifidobacterium longum 
(w/ inulin-oligofructose) 
Improve full clinical appearance of 
chronic inflammation in ulcerative 
colitis patients  
18 patients d 
Saccharomyces boulardii 
Reduce the risk of recurrence of C. 
difficile infection 
124 patients e 
Table 1. Health benefits of ingested probiotics (bacteria and yeast) with clinical evidence. 
a. (Panigrahi et al., 2017) b. (Liévin-Le Moal & Servin, 2014) c. (Lin et al., 2005) d. (Furrie et al., 
2005) e. (McFarland et al., n.d.) All clinical studies listed here are randomized, blinded, and placebo-
controlled. 
  
1.2 Synthetic Biology: Design Living Diagnostics and Smart Therapy 
Adding to the advantage of microbiota-modulating strategies, synthetic biology 
offers new opportunities to create novel functions for beneficial intervention in the 
management of GI disorders (Cameron, Bashor, & Collins, 2014; Mimee, Citorik, & Lu, 
2016; Piñero-Lambea et al., 2015). Synthetic biology leverages our knowledge of genetic 
regulation and manipulation, aiming to create novel biological functions and system 
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behaviors through the creation of new genetic parts and/or assembly of genetic circuits 
(Cameron et al., 2014; Kobayashi et al., 2004). Following this rationale, we could, for 
example, build smart bio-sensors for in situ diagnosis of diseases, or a programmable 
response with desired functions such as memory.  
Researchers are now actively exploiting the functions of probiotics through genetic 
engineering, owing to advantages of probiotic bacteria as vectors to deliver therapeutics 
to the gut (Paton, Morona, & Paton, 2006; Piñero-Lambea et al., 2015; Sheth et al., 2016; 
L Steidler, 2003). Self-proliferation and easy maintenance make them a cost-effective 
option, and they provide a way to evade gastric acid degradation of the therapeutic 
molecules and improve the delivery efficiency. In addition, genetic engineering may 
bring benefits such as improved specificity, which can be achieved through specific 
sensors or targeted actuators (F. Duan & March, 2010; Gupta, Bram, & Weiss, 2013; 
Saeidi et al., 2011). Concerns on potential release of genetically modified organisms into 
the environment are continuously addressed by new biocontainment measures, including 
an environmental signal-triggered suicidal circuit (Chan, Lee, Cameron, Bashor, & 
Collins, 2015), or development of auxotroph mutants that require supplementation of an 
essential nutrient (Zhu et al., 2015).  
The following two sub-sections provide a few examples of engineered probiotics or 
commensal bacteria for proof-of-concept strategies, as well as real-world medical 
applications. 
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1.2.1 Therapeutic Microbes 
Microbes have been engineered to deliver therapeutic functions to the gut through 
interactions with the host metabolism and physiology. A pioneering study in 2000 
(Lothar Steidler et al., 2000) utilized L. lactis as a host to produce the anti-inflammatory 
cytokine interleukin-10 (IL-10) in the intestines. Due to the effective survival rate of L. 
lacits in the GI tract and in situ production of the therapeutic molecules at the 
inflammation site, the microbe-based method proved to be ten times more effective in 
treating colitis than oral administration of the molecules. A similar strategy was used by 
Duan et al. (F. F. Duan, Liu, & March, 2015) to deliver the glucagon-like-peptide-1 using 
Lactobacillus gasseri. In a rat model, the engineered probiotics were administered twice a 
day for 90 days and reduced hyperglycemia. In addition to therapeutic molecule 
production, microbes can also provide therapeutic functions by interfering with the host 
metabolism. Research effort at Synlogic Inc. has focused on delivering engineered 
microbes that complement the missing metabolic functions in certain rare disease 
patients, such as hyperammonenia and hyperphenylalaninemia (Falb, Isabella, Kotula, 
Miller, Millet, et al., 2017; Falb, Isabella, Kotula, Miller, & Suman, 2017). 
Engineered microbes were also designed to interfere with pathogen signaling 
pathways in order to counter infections. In one example, E. coli was modified to produce 
the quorum-sensing molecules of V. cholerae, which represses the expression of 
virulence factors if present at high concentrations (F. Duan & March, 2010). Such signal 
interruption proved to enhance host survival from infections in a mouse model. One more 
example using engineered E. coli to counter V. cholerae infection is the design of a short 
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peptide that mimics the cholera toxin receptors on the human intestine epithelial cells 
(Focareta, Paton, Morona, Cook, & Paton, 2006). This peptide competes with the native 
receptor to bind to the toxins and reduce the chance of cholera toxins entering epithelial 
cells and inducing massive diarrhea. 
1.2.2 Smart Biosensors 
A few groups have leveraged the closely-related quorum-sensing (QS) systems in 
Gram negative bacteria, and engineered E. coli-based smart biosensors that detect 
specific pathogen signals and actuate a killing function. Two such works (Gupta et al., 
2013; Saeidi et al., 2011) ported the Pseudomonas aeruginosa QS molecule receptor 
LasR into E. coli and linked the circuit to the production and release of Pseudomonas-
specific bacteriocins. In another example (Holowko, Wang, Jayaraman, & Poh, 2016), E. 
coli was engineered to express the V. cholerae QS molecule receptor and corresponding 
downstream regulators to detect the presence of the pathogen and respond with an 
intracellular production of fluorescent proteins. 
 In addition to pathogen sensing, E. coli was also engineered to detect inflammation 
markers, such as tetrathionate (Daeffler et al., 2017; Riglar et al., 2017). Through 
bioinformatics mining, a few candidate receptors from Salmonella spp. were identified 
and tested in E. coli. Three functional receptors were independently verified by the two 
groups, which successfully demonstrated inflammation-sensing by engineered E. coli in 
mouse models. Riglar et al. further coupled the signal transduction with a previously 
developed memory element (Kotula et al., 2014), which is a cI and cro-based toggle 
switch, and achieved long-term maintenance of the positive output signal in the sensor 
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bacteria. 
Such microbial therapeutics and smart biosensors with desirable sense-and-respond 
functions are good examples of how synthetic biology enables further exploitation of 
commensal and probiotic microbes. Such bioengineering strategies leverage microbes’ 
versatile sensing capabilities of diverse chemical signals, as well as their superior ability 
to synthesize protein products that are difficult to produce through chemical synthesis. 
 
1.3 Lactococcus lactis 
L. lactis is a food-associated bacterium that has been safely consumed for millennia 
as part of fermented milk products (Teuber, 1995). L. lactis’ strong acidification 
capabilities stem from its high carbon flux metabolism, which is optimized for the 
conversion of simple carbohydrates into primarily lactic acid (Papadimitriou et al., 2016; 
Teusink, Bachmann, & Molenaar, 2011). This property has made it one of the most 
important fermentation starter strains during cheese making and the production of other 
dairy foods, by utilizing lactic acid’s antimicrobial properties to preserve food for a 
longer time (Mohammed Bahey-El-Din & Gahan, 2010).  
In addition to its use in the dairy industry, there is also increasing interest and effort 
in strain engineering of L. lactis for medical applications. L. lactis is genetically 
amenable, with known constitutive and inducible gene expression systems (Gasson, M J; 
De Vos, 1994), including the widely used nisin-inducible gene expression pathway (Igor 
Mierau & Kleerebezem, 2005). These genetic systems and newly developed synthetic 
biology tools (Levskaya et al., 2005; Möglich, Ayers, & Moffat, 2008; Skerker et al., 
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2008; B. Wang, Barahona, Buck, & Schumacher, 2013) provide the means to create new 
functions for novel applications, as seen in the previous example of IL-10 production and 
more examples of mucosal vaccine delivery by surface display of antigens (M Bahey-El-
Din, 2012; Raha, Varma, Yusoff, Ross, & Foo, 2005; Young, Narita, & Narita, 2011). 
Moreover, the physiological traits of L. lactis in the GI tract also make it an attractive 
candidate for microbiota-modulating applications (S Drouault, Corthier, Ehrlich, & 
Renault, 1999; Papadimitriou et al., 2016). One such trait is the high survival rate through 
the gastric acid; more than 90% of L. lactis can live through the stomach. Another 
beneficial trait is its metabolically active state throughout the GI tract, which makes it 
possible to process an environmental signal or to produce therapeutic molecules.  
 
In this work, I first show that the interaction between transiting probiotic bacteria (L. 
lactis) and invading pathogens (V. cholerae) can effectively control disease progression 
(Chapter 2). Then, I demonstrate the application of synthetic biology in building a 
probiotic-based living diagnostic that reports the presence of the pathogen in an infant 
mouse model (Chapter 3). Lastly, I propose a generalizable therapeutic peptide delivery 
system with engineered L. lactis (Chapter 4) and conclude with future directions (Chapter 
5).   
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CHAPTER TWO: PROPHYLAXIS BY NATURAL PROBIOTICS 
2.1 Introduction 
Diarrhea is among the leading causes of deaths worldwide, and is the second 
highest cause of death among children under 5 years old (WHO, 2017). Among the 
different diseases causing diarrhea, cholera is one of the most significant contributors 
with a long-lasting ongoing pandemic. Based on official case reports between 2008 to 
2012, there are 69 countries in the world that are endemic for cholera, totaling 2.9 million 
cases and 95,000 deaths each year (Ali, Nelson, Lopez, & Sack, 2015). It constitutes a 
major health burden in endemic areas of Asia, Africa and Central and South America (Ali 
et al., 2015). Occasional regional outbreaks of cholera can cause massive morbidity and 
mortality in a short period of time. As seen in the recent outbreak in the war-torn country 
Yemen, an estimate of half a million people have had contact with cholera, and more than 
2000 lives were lost within four months (Branswell & Bronshtein, 2017). Cholera is 
caused by the water-borne bacterium Vibrio cholerae. After ingestion of contaminated 
food or water, most V. cholerae cells die in the acidic environment of the stomach 
however, cells that survive colonize pH-neutral regions small intestine where they 
multiply and secrete diarrhea-eliciting factors, which in turn disseminates the bacterium 
back into aquatic reservoirs(Almagro-Moreno, Pruss, Taylor, Taylor, & DiRita, 2015). 
Severe dehydration from cholera can lead to death within hours if treatment is not 
provided promptly (Almagro-Moreno et al., 2015). Additionally, cholera transmission is 
particularly high within household contacts (Sugimoto et al., 2014). Therefore, there is an 
urgent need for control measures that prevent the development of the infection and offer a 
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timely differential diagnosis, so that isolation, sanitation and first-line therapeutic 
measures are applied on time to prevent further health complications and reduce the 
epidemic potential. 
Currently there is no specific treatment of cholera. Patients rely on rehydration to 
recover from active infection. Antibiotics are not commonly prescribed to cholera 
patients except for severe cases. However, in cholera endemic regions, people often self-
prescribe antibiotics in an attempt to avoid infection, which had led to prevalent antibiotic 
resistance in V. cholerae (Weil et al., 2009). Therefore, prophylaxis and treatment 
measures that are independent of the use of antibiotics are urgently needed. As introduced 
in the previous chapter, there is evidence that the commensal bacterium could resist V. 
cholerae colonization in the gut (Hsiao et al., 2014). Specifically, Ruminococcus obeum 
is enriched in patients recovered from cholera, and this species may be able to interrupt V 
cholerae’s colonization and pathogenicity factors through a quorum-sensing-related 
mechanism. In other work, engineered E. coli that produces the quorum-sensing 
molecules of V. cholerae can also repress V. cholerae virulence factors and thus rescue 
the host from death of diarrhea (F. Duan & March, 2010). In addition, bacteriophages 
were also explored as an option to treat V. cholerae infection (Yen et al., 2017). A 
combination of three Vibrio phages were used together to significantly reduce the 
pathogen burden in the gut.  
In this work, I present the discovery that L. lactis, a non-colonizing lactic acid 
bacterium, is also able to reduce V. cholerae burden in infected mouse gut and 
significantly improve host survival. I further demonstrate that this protection effect may 
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be due to a different mechanism than any of the previous examples, which is dependent 
on the metabolic interactions between the species.  
2.2 Results 
2.2.1 In vitro Co-culture Studies 
 Given that V. cholerae is known to be particularly sensitive to acidic conditions 
(Martinsen, Bergh, & Waldum, 2005), we investigated whether L. lactis-derived lactic 
acid is able to antagonize the growth of the cholera pathogen under co-culture conditions 
(Figure 2). We found that acidification of the surrounding environment enables L. lactis 
to outcompete the growth of V. cholerae. This antagonistic effect is no longer present 
when the principal lactate dehydrogenase gene (ldh) of L. lactis is mutated, which 
indicates that lactic acid production is necessary to inhibit V. cholera growth (Figure 2a).  
Characterization of the growth dynamics in liquid co-culture indicates that a rapid decline 
in the V. cholerae population occurs when the pH of the medium drops to 4.5 (Figure 2b). 
This bactericidal effect is completely abolished when the medium contains a strong 
buffering agent, indicating that acid production, and no other metabolic product, is the 
cause of the antagonism of L. lactis over V. cholerae in vitro. Notably, a population of 
~109 cells/ml of V. cholerae cells was reduced to undetectable levels after 8 hours of co-
culture with L. lactis and long-term co-culture did not result in the re-emergence of a 
viable V. cholerae population. These results indicate that lactic acid, the main product of 
L. lactis metabolism, is a powerful cholera-antagonizing compound. 
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Figure 2. Lactic acid-dependent antibacterial effect of L. lactis against V. cholerae in vitro. 
(a) In an agar diffusion assay, wildtype L. lactis outcompetes an adjacent V. cholerae colony, whereas 
a lactate dehydrogenase mutant (∆ldh) with impaired acidification does not. Minimally buffered 
GM17 agar plates contain pH indicator bromocresol purple that turns yellow when pH drops below 
5.2. (b) In liquid medium, V. cholerae was eliminated when co-cultured with L. lactis in minimally 
buffered media. Additional pH buffer in the media (+buffer) abolishes the antibacterial effect. For 
detailed media conditions, see Methods and Figure 6. Error bars are SEM of technical duplicates. 
2.2.2 Mouse Survival Studies 
We hypothesized that lactic acid production by L. lactis could be harnessed as a 
potential therapeutic strategy to reduce the burden of cholera infection. Intervention with 
a high dose ingested bacterial cells is likely to induce a population shift that temporarily 
overcrowds resident communities and has the potential to alter the intestinal 
microenvironment (Derrien & van Hylckama Vlieg, 2015). Both L. lactis and V. cholerae 
are transient microbes of the gastrointestinal tract that find temporary residency and are 
metabolically active in the small intestine (S Drouault et al., 1999; Millet et al., 2014). 
Hence, this transient niche overlap might provide a window for L. lactis to inhibit V. 
cholera at the onset of the infection. To evaluate this potential therapeutic intervention 
we used the suckling mouse model for cholera infection (F. Duan & March, 2010; Klose, 
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2000). We established a feeding regime that ensured a sustaining presence (one dose 
every 10 hours, transiting dynamics see Figure 5) of L. lactis after infant mice had been 
co-inoculated with ~107 cells of V. cholerae and ~109 cells of L. lactis (Figure 3a). 
Strikingly, we observed a significant increase in the mean percent survival of infection in 
mice fed with L. lactis compared to mock-fed mice after 40 hours of infection (Figure 3b). 
Three independent trials suggest this improved survival by L. lactis treatment is not 
significantly affected by litter variation (Figure 3c). More importantly, the protection 
effect is not dependent on administration schedule. A co-administration and a 5-hour pre-
administration schedule both gave similar protection results (Figure 3b). The survival 
dynamics from these trials indicates that between 22 to 32 hours post-infection there is a 
window where the infection fully develops and the mortality rate is the highest. In fact, 
evaluation of the colonization within this window (26h post-infection) showed that the V. 
cholera burden in mice fed with L. lactis was reduced two orders of magnitude compared 
to untreated mice (Figure 3d). Importantly, a reduced V. cholerae burden can be related 
to a survival outcome of the infection because, independently of whether mice were fed 
with L. lactis or not, all of the ones that survived the infection also displayed lower levels 
of V. cholera colonization (Fig. 2d). These results demonstrate that a regular feeding 
regime of L. lactis is able to prevent the full development of cholera infection and keep 
the bacterial burden to non-lethal levels in infant mice.  
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Figure 3. L. lactis–derived lactic acid antagonizes V. cholerae infection in the infant mouse 
model. 
 (a) Intragastric feeding regimes of L. lactis and inoculation time of V. cholerae to infant mice. Mock-
fed mice were administered GM17 medium instead of L. lactis. (b) L. lactis intervention improves 
infant mouse survival to cholera infection under both feeding regimes. Co-administration with V. 
cholerae ***P = 0.0005, pre-administration *P = 0.0187, log-rank test against mock-fed (V). n (V) = 
37, N (V) = 6; n (V+L, co-admin) = 39, N (V+L, co-admin) = 6; n (V+L, pre-admin) = 19, N (V+L, 
pre-admin) = 6. (c) Litter variation does not affect the outcome significantly. Each data point 
represents a litter of infant mice. P(treatment)=0.0385, P(litter)=0.6325 with two-way ANOVA. (d) L. 
lactis reduces V. cholerae burden in the mouse gut (left). Viable V. cholerae cells recovered from gut 
at 26 h reached 109 in non-treated mice, whereas the median was reduced two orders of magnitude in 
L. lactis-treated mice. V. cholerae load correlates with infection outcome (right). Regardless of 
feeding regime, mice that died from cholera have V. cholerae developed to 109 in the gut; the ones 
that survived until the end of study had lower than 108. Each data point represents an individual mouse. 
Horizontal lines are medians. P values from Mann Whitney test (n = 7, N = 7 for non-treated/treated; n 
= 11, N = 7 for dead/survived). (e) L. lactis intervention results in higher lactate concentration in the 
gut at 26 h post-infection. Mann Whitney test (n = 7, N = 7). 
2.2.3 Mechanistic Studies 
We hypothesized that lactic acid production during the intervention with L. lactis 
contributes to the protection against V. cholerae by creating an acidic environment that is 
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unfavorable for the progression of the infection. In line with this notion, we found that 
after 26h post-infection, time at which 3 doses had already been given, mice that were fed 
with L. lactis had increased levels of lactate in the gut compared to mice that were mock-
fed (Figure 3e). Additionally, when heat-inactivated cells were used instead of live L. 
lactis, the survival rate of the treated mice was similar to the mock-fed group, indicating 
that metabolically active L. lactis is necessary to exert an effective protection (Figure 4a). 
To further relate the protection effect to the production of lactic acid, we used in the 
feeding regime a lactate dehydrogenase (ldh) mutant strain of L. lactis (Figure 4c) and 
found that the protective effect was compromised (Figure 4b), indicating that lactic acid 
production is required to increase the survival to the infection. Furthermore, when we 
restored the acidification capabilities in the ldh mutant strain by expressing a plasmid-
encoded ldh gene, the survival of the mice increased to levels similar to wild type L. 
lactis (Figure 4b). We also examined the lactic acid-mediated inhibition hypothesis by 
using an acid-acclimated V. cholerae (Merrell & Camilli, 1999). We induced the Acid 
Tolerance Response (ATR) in V. cholerae by incubating the cells for a short period of 
time in growth media whose pH was adjusted to 6.1 with lactic acid. This treatment 
increased the tolerance of cells to rapid changes in the pH (Figure 4d). As expected, mice 
challenged with this strain were not protected by L. lactis intervention (Figure 4e), 
indicating that V. cholerae with increased tolerance to acidic conditions are not subject to 
the antagonistic effect of L. lactis in the mouse gut.  These results suggest that lactic acid-
mediated inhibition of V. cholera colonization is the principal mechanism by which L. 
lactis exerts its protective effect in the infant mouse model of cholera infection.  
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Figure 4. Lactic acid produced by L. lactis plays a significant role in the prophylactic effect 
against cholera infection. 
 (a) Heat-inactivated L. lactis does not protect infant mice from cholera. n = 10, N = 3.  (b) Functional 
knockout of lactate dehydrogenase (∆ldh) compromises the protective effect against cholera (n = 20, N 
= 6). ns: not significant by log-rank test comparing to no-treatment (V). Complementation with a 
plasmid-based ldh restores the protection effect (*P = 0.0349 log-rank test, n = 9, N = 3). n, number of 
individual mice; N, number of litters covered in each group. (c) Growth and acidification capability of 
L. lactis wildtype and the lactate dehydrogenase (ldh) mutants. The lactate dehydrogenase mutant 
(∆ldh) has slower growth rate and significantly impaired acidification capability compared to wildtype. 
When complemented with a plasmid that has a constitutively expressed ldh gene (pLDH), the growth 
rate and acidification capability are restored. (d) Enhanced acid tolerance of V. cholerae by 
acclimation in vitro. V. cholerae cells acclimated in mild acid (40 mM lactic acid, pH 6.1) show 
enhanced tolerance to more acidic environment, where natural (unacclimated) V. cholerae is killed. (h) 
V. cholerae acclimated to mild acid conditions (pH 5.8) in vitro overcomes the inhibition by L. lactis 
in vivo. n=9, N=3 for each arm with V(acd). 
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Figure 5. V. cholerae and L. lactis population dynamics in mouse gut. 
(a) Natural V. cholerae (5*107 CFU in inoculum) viable cell count in the gut decreases during the first 
few hours in the gut; towards the end of the first 10 h, the pathogen establishes colonization in the gut 
and rapidly develop to a high density (over 109) (blue).  The acid acclimated V. cholerae readily 
overcomes the acidic environment in the GI tract and goes straight into the developing phase (green). 
Error bars are SEM of biological triplicates. (b) L. lactis population drops over time in both the small 
and large intestines (3*108 CFU in inoculum), but it stayed at a density above the detection limit for at 
least 10 hours.  Error bars are SEM of biological duplicates. 
 
 2.3 Discussion 
We demonstrated that intestinal intervention with L. lactis, through its lactic acid 
production and acidification of the gut environment, could effectively ameliorate the 
cholera burden in infant mice. However other contributing factors not studied here might 
also antagonize V. cholerae infection. For instance, lactic acid was shown to permeabilize 
the outer membrane of Gram-negative bacteria, making them more sensitive to other 
antimicrobial compounds (Alakomi et al., 2000). Also, lactose fermentation products of L. 
lactis can affect motility of intestinal pathogens including V. cholerae (Nakamura, 
Morimoto, Kudo, & Shuichi Nakamura, 2015), which might reduce dissemination of the 
pathogen in the intestinal milieu. Microbiota-derived lactate was also reported to promote 
epithelial cell turnover in mice (Okada et al., 2013): a physiological effect that might 
interfere with colonization. In addition, lactate may exert multiple immunomodulatory 
effects similar to other short chain fatty acid metabolites that might contribute to a better 
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protection from infection in the gut (Garrote, Abraham, & Rumbo, 2015; Rooks & 
Garrett, 2016). However, due to the immaturity of the infant mouse immune system it is 
unclear how this might have contributed to the observed protection to infection in our 
study. 
The capacity of the protection effect might be further subject to the individual 
gastrointestinal environment of the host. The distal part of the small intestine is highly 
variable in terms of pH (Fallingborg, 1999). In subjects with a neutral or slightly basic 
intestinal environment, the L. lactis-based prophylaxis may be more significant and 
differentiable; in contrast, for subjects with a low small bowl pH to begin with, the 
protective effect exerted by ingesting L. lactis may be limited. In addition, as the gut 
environment and the gut microbiota are also dependent on the diet and potential drug 
intake, the prophylactic outcome could be influenced by these factors as well.  
2.4 Conclusion 
The microbiota-modulating capacity of a transient (i.e. non-colonizing) species for 
the management of an acute infectious disease has been explored here. We utilize the 
natural ability of the food-associated lactic-acid bacterium, Lactococcus lactis, to acidify 
the intestinal environment and inhibit the growth of Vibrio cholerae with significant 
improvements in host survival. The consumption of affordable, readily available, 
fermented food products containing live L. lactis may not only improve the outcome of 
initial infections through direct reduction of pathogen burden, but also provide an 
alternative measure to counter the wide-spread antibiotic resistance. The use of biological 
prophylaxis, such as the probiotic intervention presented here, could serve as an 
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alternative to conventional chemoprophylaxis and limit the emergence of antibiotic 
resistance in the population (Weil et al., 2009).  
2.5 Methods 
Bacterial strains 
Vibrio cholerae strain C6706 (O1 El Tor biotype) was grown in Luria-Bertani (LB) 
broth at 37 °C for animal experiments. V. cholerae C6706 containing an inactivating 
transposon insertion in the cholera toxin gene ctxA (C6706ctxA) (Cameron, Urbach, & 
Mekalanos, 2008) was used for in vitro experiments. Lactococcus lactis subsp. cremoris 
MG1363 was used throughout the study. L. lactis was maintained at 30 °C in DifcoTM 
M17 medium supplemented with 0.5% glucose (GM17) unless otherwise stated. 
Co-cultures 
L. lactis-V. cholerae (L-V) co-culture was used to test hybrid receptor and the 
cholera-sensing circuit performance in vitro. To maintain viable V. cholerae cells in the 
co-culture, GM17 was additionally conditioned with 50 mM phosphate buffer at pH 7.0 
(GM17-buffered). 1M stock of the phosphate buffer was made with KH2PO4 4.68 g + 
Na2HPO4 16.4 g in 100 ml DI water (recipe from Sigma Aldrich). Overnight culture of V. 
cholerae was diluted 1:1000, and L. lactis 1:100 in GM17-buffered, and allowed to grow 
to exponential phase (OD600 0.2–0.4). Then a new tube of 2 ml GM17-buffered was 
inoculated with 100 µl L. lactis and 1 µl V. cholerae, and was incubated at 37 °C with 
shaking. Samples were taken at 2-hour intervals for flow cytometry analysis of 
fluorescent output. For high throughput screening, the co-culture was inoculated in 96-
well plates, and the volumes were scaled accordingly.  
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The steady-state cell density of V. cholerae in an L-V co-culture in GM17 medium 
with no additional buffering was 2-log lower than a V. cholerae monoculture or an L-V 
co-culture in GM17-buffered (Figure 6a). To examine the true efficacy and dynamics of 
V. cholerae killing by L. lactis, a GM17 medium with no buffer was made according to 
BD Difco M17 broth recipe, but containing no disodium-β-glycerophosphate. pH 7.0 
phosphate buffer was added at 12.5 mM to eliminate the self-inhibitory effect of V. 
cholerae growing on glucose (Yoon & Mekalanos, 2006) (Figure 6b). This minimally 
buffered GM17 was inoculated with L. lactis and V. cholerae at 100:1 ratio and sampled 
every hour for drop-plate CFU count of each species. 
  
Figure 6. L. lactis-V. cholerae co-culture system. 
(a) Optimization of extra-buffered GM17 for V+L co-culture. The commercial GM17 medium 
requires at least 10 mM additional phosphate buffer to eliminate the antibacterial effect of L. lactis in 
L+V co-culture. (b) Optimization of minimally-buffered GM17 for V+L co-culture. V. cholerae 
growing on glucose in customized GM17 medium with no β-glycerophosphate inhibit its own growth. 
A minimum of 12.5 mM inorganic phosphate buffer is needed to eliminate this self-inhibitory effect. 
(c) V+L co-culture system. GM17 media with extra buffer (B+) contains 87.95 mM disodium-β-
glycerophosphate and 50 mM phosphate (HPO42-/H2PO4-). Minimal buffer medium (B-) contains 12.5 
mM phosphate buffer. 
 
Animal husbandry 
All mice in this study were treated in accordance with protocol IS00000852, 
approved by Harvard Medical School Institutional Animal Care and Use Committee and 
the Committee on Microbiological Safety. A litter of white CD-1 infant mice were 
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purchased from Charles River Laboratories at postnatal day 1 with mother in a micro-
isolator cage, and housed in BL2 animal facility for 72h of acclimation before each study. 
Mouse survival from cholera 
The cholera survival protocol was modified from Duan and March (F. Duan & 
March, 2010). 4-day old suckling mice were separated from mother and kept in a 30 °C 
incubator for 2 hours to digest the milk in stomach. Overnight bacterial cultures were 
washed and resuspended in GM17 to appropriate density (L concentrated by 5 fold, V 
diluted by 5 fold). 25 µl of the bacteria was administered to each mouse intragastrically, 
containing (1~5) × 107 V. cholerae cells and (0.5~1)	  × 109 L. lactis cells, at time 0 h. 
Subsequent L. lactis doses were given every 10 hours for three times. After each feeding, 
the mice were monitored for at least 15 min until they recovered from anesthesia, and 
then returned to the dam. The mice were monitored for 42 hours for survival and 
sacrificed at the end of study. The small and large intestines of the mice were collected in 
1 ml PBS and homogenized with an HT Mini high throughput homogenizer (OPS 
Diagnostics).  Serial dilutions of the homogenate were plated for L. lactis and V. cholerae 
cell counts.  
To reduce the total number of mice needed in each trail without compromising the 
power of the study, the survival studies were performed in a randomized cross-litter 
manner (Festing, 2006) (with the exception of the pilot study in Figure 3c). Each trial was 
performed with at least three litters. Each litter was randomly divided into 3 groups with 
a random number generator. Each group was assigned to a different treatment. Overall, 
each treatment covered individual mice from at least 3 litters. No blinding was performed 
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in either experiments or data analysis. Sample sizes were determined by power analysis 
to reach a statistical power of 0.8 or higher, using the pwr package (Champely, 2016) in 
R (Core Team, 2016). Survival analysis (log-rank test) and other statistics were 
performed with GraphPad Prism 5.0c. 
L. lactis heat inactivation 
Stationary-phase L. lactis cells were collected, washed, and resuspended to 
appropriate density for inoculation. Then the culture was aliquoted to 50 µl and heated at 
70 °C for 30 min. The heated bacteria were plated for viability test before inoculation. 
The final inoculum contained less than 10 viable units of L. lactis administrated to the 
mouse. 
Lactate quantification 
Homogenized gut tissue was pelleted, supernatant filtered with a 0.2 µm filter, and 
then spun in a 10K Microcon centrifugal filter unit (EMD Millipore) to eliminate lactate 
dehydrogenase. Filtered samples were stored at -80 °C until assayed. Lactate assay kit 
from Sigma Aldrich (MAK064) was used, and the quantification procedure followed the 
kit instructions. Briefly, samples were diluted to 3/100 of original concentrations in the 
assay buffer, so that the final concentrations fall into the range of standard curve. The 
diluted samples were mixed 1:1 with the enzyme master mix prepared from the kit and 
incubated at room temperature for 30 min. The absorbance at 570 nm was read on a 
SpectraMaX M5 (Molecular Devices). The concentrations of the samples were calculated 
from the standard curve. Each sample, including the standard curve, was run in duplicate. 
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CHAPTER THREE: ENGINEERED LIVING DIAGNOSTIC 
3.1 Introduction 
Laboratory bacteria have been engineered as living diagnostics that can detect the 
presence of pathogens (Gupta et al., 2013; Holowko et al., 2016; Saeidi et al., 2011) (see 
Chapter 1). However, incorporation of such bio-sensing circuits into relevant food-grade 
bacteria and the validation of this diagnostic function in animal models remain to be 
demonstrated. 
In this work, we show that the food-grade lactic acid bacterium L. lactis can be 
engineered into a living diagnostic that detects and reports V. cholerae presence in situ. 
We demonstrated in the last chapter that during the probiotic intervention, metabolic 
products from L. lactis interact with V. cholerae, leading to an amelioration of the 
infection. Similarly, during this period of co-localization in the intestine, metabolic 
products derived from V. cholerae might interact with L. lactis cells, an event that could 
be exploited to detect the presence of the pathogen at an early stage of infection. We 
applied a synthetic biology approach to engineer L. lactis into a living diagnostic that 
detects a unique chemical signal from the pathogen, and in response produce an 
orthogonal reporter whose signal could be evident directly from fecal samples. The 
cholera autoinducer-1 (CAI-1) is a quorum-sensing molecule highly specific to V. 
cholerae that regulates biofilm formation and virulence gene expression (Higgins et al., 
2007). Therefore, we set out to create a CAI-1 sense-and-respond function for L. lactis 
that will convert this bacterium into a living diagnostic for cholera infection. We further 
utilized an enzymatic reporter that is stable and orthogonal to the chemical components 
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of the feces. Activation of the diagnostic circuit leads to production and secretion of this 
reporter into the colon, and subsequent readout of the reporter can be done through a 
simple colorimetric assay.  
  
Figure 7. Proposed strategy of oral administration of L. lactis for cholera protection and 
diagnosis. 
The natural lactic acid bacteria acidify the intestinal environment to antagonize the growth of the 
pathogen. The engineered probiotics detect the quorum-sensing molecule of V. cholerae and produce 
an enzymatic reporter, which can be detected by a colorimetric assay with fecal samples. On the right 
are two possible ways of performing the colorimetric assay on fecal samples, and their corresponding 
readouts. 
  
3.2 Results 
3.2.1 Hybrid Receptor 
We sought to engineer a hybrid receptor (HR) for CAI-1 that incorporates the 
ligand-binding domain of CqsS, the native receptor of CAI-1 (Higgins et al., 2007), and 
the signal transduction domain of NisK, a histidine kinase from L. lactis that is natively 
induced by the lantibiotic nisin (Igor Mierau & Kleerebezem, 2005) (Figure 8a). We 
designed 10 variants of the CqsS-NisK hybrid receptors that differed in the junction 
sequence between the two non-cognate domains (Figure 14a). Additionally, each variant 
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of the HR incorporated a library of randomized ribosomal binding site (RBS) sequences 
to test varied expression levels from the constitutive promoter PnisR (Figure 14b). We 
screened the HR library for a functional variant that responds to CAI-1 by modulating the 
gene expression of a fluorescent reporter driven by the nisA promoter. Because the CAI-1 
molecule is short-lived (Kelly et al., 2009), we carried out the screening in a co-culture 
system, where each HR-expressing L. lactis clone was grown with wild type V. cholerae 
as a CAI-1-positive condition, and also with a V. cholerae deficient in the production of 
CAI-1 (ΔcqsA) as a CAI-1-negative control (Figure 8b).  
While most HR were not responsive to CAI-1 (Figure 14c), we found a functional 
hybrid receptor variant containing a Glu to Gly mutation at residue 182 (HR4-E182G) 
that displayed a 10-fold repression of the reporter gene only in presence of CAI-1 (Figure 
8c, d). Further characterization of the induction dynamics of L. lactis cells expressing 
HR4-E182G showed that the CAI-1-dependent modulation of gene expression was 
observable as early as 4 hours of co-culture with wild type V. cholerae (Figure 8e), when 
V. cholerae density was between 107 to 108 CFU/ml (data not shown). Also, the reporter 
gene expression dynamics of L. lactis cells expressing HR4-E182G in co-culture with the 
cqsA mutant strain shows no significant difference with the dynamics of cells growing in 
monoculture, which indicates that the HR-dependent gene regulation is not altered by 
other metabolites from V. cholerae (Figure 8c, e). Interestingly, these results indicate that 
this functional HR conserves the phosphorelay properties of CqsS; autophosphorylation 
and phosphotransfer to downstream transcription factors when the CAI-1 ligand is not 
bound, and ceased phosphorylation when CAI-1 is bound. 
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Figure 8. Construction of hybrid receptor for V. cholerae sensing. 
(a) Creation of a CAI-1-sensing function in L. lactis requires the fusion of two distantly related 
quorum-sensing signaling pathways. The proposed hybrid receptor (HR) fuses the CAI-1-binding 
domain of the CqsS receptor with the histidine kinase domain of NisK to achieve CAI-1-dependent 
signaling in L. lactis. The theoretical design cannot predict whether the regulatory outcome of CAI-1 
binding will be activation or inactivation of NisR. (b) Functional screen for hybrid receptor variants. 
Ten CqsS-NisK fusion variants with randomized RBS strengths (Extended Data Fig. 5) were screened 
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for their ability to modulate output gene expression in response to CAI-1. CAI-1-deficient V. cholerae 
(V ∆cqsA) serve as a negative control. (c) A Hybrid Receptor 4 mutant (HR4M) responds to CAI-1 by 
repressing the output gene. mCherry expression levels in the CAI-1-induced population display little 
overlap with inactive populations. Hybrid Receptor 2 (HR2) is an example of a non-functional hybrid 
receptor. (d) Primary sequence map of HR4M. S177 indicates the last residue of N-terminal part of 
CqsS, and A221 indicates first residue of the C-terminal part of NisK. The hybrid receptor contains a 
spontaneous Glu to Gly mutation at residue 182. (e) Reporter gene expression dynamics in L. lactis 
with HR4M. mCherry expression is gradually repressed by HR4M after continued co-culture with 
CAI-1-producing V. cholerae. Error bars are SEM of three technical replicates. 
3.2.2 Invertor Circuit 
To produce a positive response upon detection of the pathogen, we coupled a 
signal inverter unit to the circuit: a tetR repressor gene and a xyltet promoter derived from 
the Bacillus subtilis xylA promoter, which incorporates two tetO sites for TetR to bind 
and repress (Geissendörfer & Hillen, 1990). We evaluated the functionality of this 
inverter unit in L. lactis and screened for an optimal expression level of TetR that allowed 
a suitable dynamic range of induction (Figure 9b). The complete cholera-sensing circuit 
works as follows: in the absence of CAI-1 ligand, constant phosphorelay from HR4-
E182G to NisR leads to continuous TetR expression, which keeps the output gene 
repressed. In the presence of CAI-1, the phosphorelay to NisR stops and TetR expression 
is turned off, which allows the expression of the output gene (Figure 9c). We 
characterized the complete cholera-sensing circuit using a fluorescent protein output 
under co-culture conditions and found that the fluorescent signal was increased 60-fold in 
response to CAI-1, with minimal signal background (Figure 9d). 
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Figure 9. Invertor circuit design and optimization. 
(a) The xyltet promoter, derived from B. subtilus, is repressed more than 30 fold by TetR in L. lactis 
with a nisin-induced tetR expression circuit. (b) TetR translation rate in the cholera-sensing circuit 
was fine-tuned for a desirable dynamic range of induction. Shown in the figure are examples of low 
(10k), medium (19k) and high (27k) levels of TetR RBS strengths. A low RBS strength results in high 
background expressions, whereas too high a translation rate leads to partial activation of the output 
gene. An appropriate TetR translation rate allows full activation of the output under induced 
conditions, and keeps a low background in the off state. (c) Engineered CAI-1-dependent signaling in 
L. lactis. The HR4M-NisR two-component system sensing module and a TetR/Pxyltet signal-processing 
module constitute the complete V. cholerae-sensing circuit. In the absence of CAI-1, constitutive 
expression of TetR prevents the expression of the output gene. In the presence of CAI-1, the hybrid 
two-component system stops its phosphorelay, halting TetR expression and leading to activation of 
the output gene. (d) Activation dynamics of the cholera-sensing circuit. The output gene (mCherry) is 
upregulated 60 fold in the L+V wt co-culture. Error bars are SEM of three technical replicates.  
 
3.2.3 Enzymatic Reporter 
Because cholera outbreaks often happen in under-developed regions, a practical cholera 
diagnostic must provide an easy point-of-care readout. We envisioned the use of a stable 
orthogonal enzymatic reporter secreted by the living diagnostic cells upon pathogen 
detection that produces a colorimetric signal when a substrate is added to the stool. To 
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achieve this, we incorporated a b-lactamase gene with an usp45 secretion signal (Le Loir 
et al., 2005) to the output module of the cholera-sensing circuit. Activity of the b-
lactamase reporter is easily identified by hydrolysis of the chromogenic substrate 
nitrocefin (Figure 10a), which turns from yellow to red. This cholera-sensing strain with 
b-lactamase reporter is termed CSL. When the sensitivity of the L. lactis CSL strain was 
evaluated by in vitro co-culture, we found that at a density of 108 CFU/ml of V. cholerae 
the CSL strain produced enough b-lactamase in the medium to generate a visible color 
change in the substrate within 30 min (Figure 10b). This result demonstrates that the L. 
lactis CSL strain is capable of producing a rapid and easy-to-read signal in response to V. 
cholerae. 
We next sought to test whether the L. lactis CSL strain is able to provide a diagnostic 
signal of cholera infection in the infant mouse model. For this, we co-inoculated infant 
mice with 107 V. cholerae and 109 L. lactis CSL cells. 10 hours later, we provided an 
additional dose of 109 L. lactis CSL cells and separated the infant mice from their mother 
to collect stool samples in the next 12 hours (Figure 10c). The fecal pellets were 
incubated with 0.1 µM of nitrocefin to detect the presence of the b-lactamase reporter. To 
evaluate the plausibility of this living diagnostic approach, we first confirmed the 
orthogonality of b-lactamase assay to the gut environment of infant mouse by showing 
that no nitrocefin color change was observed in fecal pellets of mice that were mock-fed, 
fed only with the CSL strain or that only received V. cholerae inoculation (Figure 10d). 
Also, feeding mice with an L. lactis that constitutively expresses the b-lactamase reporter 
(L. lactis b-lact+) proves that this enzyme is stable in the gut environment and a strong 
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colorimetric signal can be obtained directly from stool samples (Figure 10d). More 
importantly, we obtained a positive signal from fecal pellets of V. cholerae-infected mice 
that were fed with the L. lactis CSL strain after overnight incubation with nitrocefin, 
which demonstrates that our living diagnostic is able to detect CAI-1 in the infant mouse 
gut environment (Figure 10d). Moreover, mice infected with a cqsA mutant of V. 
cholerae and fed with the L. lactis CSL strain did not produce any signal, demonstrating 
that the diagnosis is specific for CAI-1 (Figure 10d). These results provide a proof-of-
concept for an engineered probiotic as living diagnostics for a home-based application in 
cholera infection.  
 
Figure 10. b-lactamase as a reporter to produce a colorimetric readout. 
(a) The chemical reaction of nitrocefin hydrolysis by b-lactamase to produce a color shift from yellow 
to red. (b) Colorimetric reporting of V. cholerae sensing in vitro. The L. lactis CSL strain secretes b-
lactamase, which hydrolyzes nitrocefin and produces a visible color change from yellow to red (max 
absorbance at 486 nm). A positive signal is visible at a V. cholerae density of 108 CFU/ml and higher. 
Error bars are SEM of technical duplicates. (c) Schematic of the infant mouse model for in vivo testing 
of the cholera-sensing strain. Cholera-infected mice were fed with L. lactis CSL, and stools were 
collected between 10–20 h post infection for nitrocefin-based b-lactamase assay. (d) Performance of 
the living diagnostic and b-lactamase assay for the diagnosis of cholera. b-lactamase proves to be an 
orthogonal and stable reporter to be used in mouse fecal samples. Color change in nitrocefin with fecal 
samples indicates that the diagnostic L. lactis CSL is only activated in the gut when the mice are 
infected with CAI-1-producing V. cholerae.  
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3.2.4 Metabolic Burden of Genetic Circuit 
When we evaluated the survival rate of mice that were fed with L. lactis CSL strain, 
we unexpectedly found that this engineered strain showed a compromised protective 
effect against cholera infection (Figure 11b). To understand the factors involved in the 
reduced therapeutic effect, we characterized the growth and acidification dynamics of the 
L. lactis CSL strain under monoculture and co-culture with V. cholerae (Figure 12). We 
found that the activation of the cholera-sensing circuit and secretion of the reporter 
enzyme creates a metabolic burden in L. lactis cells. Consequently, it reduces the 
acidification capabilities of L. lactis and affects the probiotic’s antagonistic effect on V. 
cholerae cells. Although this is an undesired effect, it further supports the hypothesis that 
lactic-acid production in the gut environment plays a key role in the protective effect. To 
achieve a combined therapeutic effect and a diagnostic function from the probiotic 
intervention, we incorporated in the feeding regime a mixed population of wild type and 
CSL L. lactis (Figure 11a). This mixed dose of engineered and natural L. lactis 
successfully restored the protection effect and provided an effective diagnostic readout 
from stools (Figure 11b, c). 
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Figure 11. L. lactis intervention for combined cholera protection and diagnosis. 
(a) Strategy of mixed population of natural and engineered L. lactis for cholera protection and 
diagnosis. The natural lactic acid bacteria acidify the intestinal environment to antagonize the 
blooming of the pathogen. The engineered probiotics detect the quorum-sensing molecule of V. 
cholerae and produce an easy-to-read reporter. (b) Infant mouse survival to V. cholerae infection after 
the intervention with single or combined L. lactis strains.  The diagnostic strain L. lactis CSL has a 
compromised protective effect against cholera. By providing a mixed population of natural and 
engineered L. lactis, the protective effect is restored to a level comparable to wildtype L. lactis. n = 18, 
N = 4 for CSL and wt+CSL, respectively. Log-rank test against mock-fed group (V): **P (wt & CSL) 
= 0.0034; ns (CSL), not significant. (c) Intervention with combined wildtype and CSL L. lactis does 
not affect the outcome of V. cholerae diagnosis.  Fecal samples collected from mice infected with V. 
cholerae and the mixed L. lactis produced a detectable color change with nitrocefin. Absorbance at 
486 nm was measured on three samples in each group. Error bars represent SEM. 
 
 
Figure 12. Metabolic burden incurred by engineered circuit. 
(a) Viable cell count of wildtype and engineered L. lactis from mouse gut. The engineered strain CSL 
has a lower median of recovered cells than wildtype, but no significant difference was detected in the 
available samples (Mann Whitney test). (b) L. lactis wildtype and CSL strain in monoculture and co-
culture with V. cholerae under anaerobic conditions. L. lactis CSL acidifies medium slower than 
wildtype (about two hours delay in monoculture). The CSL strain density drops in L+V co-cultures, 
and the steady-state pH is significantly higher than the co-culture with wildtype L. lactis. These results 
indicate a metabolic burden associated with the engineered circuit and compromised fitness when the 
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circuit is activated. (c) Nitrocefin assay with the supernatant and V. cholerae cell viability in the L+V 
co-culture. Increased absorbance at 486 nm demonstrates activation of cholera-sensing circuit in CSL 
strain. V. cholerae-killing by L. lactis CSL is delayed by 4 hours compared to wildtype. Error bars are 
SEM of technical duplicates. 
 
3.3 Discussion 
We provide the first demonstration of the use of an engineered living diagnostic 
strain of L. lactis that effectively identifies pathogen-specific signals in an animal model 
and provides a visible report of infection. The deployment of such living diagnostics into 
cholera endemic areas still have challenges that need to be addressed. First, the 
orthogonality of the b-lactamase reporter might be compromised if used in a patient 
under treatment with b-lactam antibiotics, as microbiota-derived b-lactamase could be 
induced and create false positives (Zeng & Lin, 2013). Second, the current readout time 
is a significant delay in getting the diagnostic result. Especially with a disease that 
progresses so rapidly, the time between getting the patient sample and obtaining the 
results is critical. Extensive optimization of the system is still necessary. Potential 
methods include enzyme evolution for an even higher catalytic capability, incorporation 
of anti-degradation tags on the enzyme that helps to boost the concentration of the 
reporter in the fecal mixture, and possible a more efficient sampling equipment that can 
produce a more obvious readout with fewer samples. Finally, the cost of nitrocefin is too 
high to be effectively utilized in large scale. Further studies to explore food-grade 
enzyme-substrate pairs as orthogonal intestinal reporters will make such systems more 
applicable to low-resource settings.  
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3.4 Conclusion 
Despite prior studies in engineering diagnostic bacteria (Daeffler et al., 2017; 
Holowko et al., 2016; Kotula et al., 2014; Saeidi et al., 2011), significant progress has 
been hindered by the lack of modular building blocks for practical design and use. We 
have created a novel hybrid cell surface receptor that directly enables the probiotic L. 
lactis to detect a biochemical signal specific to V. cholerae. This hybrid receptor and 
coupled genetic circuit design provides a molecular architecture strategy for generalizable 
“sense-and-respond” bioengineering. 
We also incorporated an enzymatic reporter that is orthogonal to the chemical 
components in the gut and stool, which allows for a convenient colorimetric assay of 
cholera infection from a patient’s fecal samples. This eliminates the necessity of 
specialized laboratory equipment like a culture incubator or a spectrophotometer for 
testing and readout.  
As demonstrated in several epidemiological studies, household contact with 
infected individuals is among the highest known risk factors for subsequent infection and 
dehydration (Weil et al., 2009). The consumption of affordable, readily available, 
fermented food products containing live L. lactis may not only improve the outcome of 
initial infections through direct reduction of pathogen burden, but the diagnostic readout 
may also alert close contacts to access aggressive prophylaxis as well as rehydration 
solutions. In addition, the use of biological prophylaxis, such as the probiotic intervention 
presented here, could serve as an alternative to conventional chemoprophylaxis and limit 
the emergence of antibiotic resistance in the population (Weil et al., 2009). Furthermore, 
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improving surveillance and the early identification of cholera cases are the two most 
important aspects of preventing further cholera outbreaks according to the World Health 
Organization (WHO, 2008). The implementation of engineered diagnostic bacteria has 
the potential to provide community-level surveillance of cholera cases and may help 
elucidate the contribution of asymptomatic carriage of V. cholerae to disease 
transmission and retention in a population (King, Ionides, Pascual, & Bouma, 2008).  
 
3.5 Methods 
Strain Engineering 
To make the cqsA deletion strain C6706ctxA ∆cqsA, V. cholerae genomic DNA 
surrounding cqsA was amplified by crossover PCR and cloned into pWM91 (Metcalf et 
al., 1996) for subsequent SacB-mediated allelic exchange, as described previously 
(Cameron et al., 2008). A GFP-integrated strain of L. lactis (MG1363G) was constructed 
using the method described by Pinto et al. (Pinto et al., 2011). The L. lactis codon-
optimized GFP gene was inserted into the llmg_pseudo_10 locus in a single integrand 
manner, conferring erythromycin resistance. The same integration strategy was used to 
interrupt the coding region of the principal lactate dehydrogenase gene of L. lactis 
MG1363 (llmg_1120). Escherichia coli NEB 10-beta (New England BioLabs) cells were 
used as intermediate hosts for plasmid construction. E. coli cells were propagated at 37°C 
in LB broth. 
Appropriate antibiotics were added to growth media for selection or maintenance of 
plasmids at the following concentrations: carbenicillin 100 µg/ml, chloramphenicol 10 
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µg/ml, and erythromycin 10 µg/ml. To enumerate wild type L. lactis from a mixed 
culture or the mouse gut homogenate, GM17-agar plates with 2 µg/ml rifampicin and 5 
µg/ml polymyxin B (modified from Ballal et al. (Ballal et al., 2015)) were used. For wild 
type V. cholerae, LB-agar plates with 70 µg/ml streptomycin were used. 
Plasmid construction 
 All plasmids were constructed in E. coli 10-beta, sequenced (Quintara Biosciences) 
when necessary, and used for L. lactis transformation. L. lactis competent cells were 
prepared  and transformed according to Holo & Nes (Holo & Nes, 1989). The plasmid 
housing the cholera-sensing circuit was derived from pECGMC (Cameron & Collins, 
2014). Plasmid map is illustrated in  
Figure 13. The backbone has a ColE1 origin of replication for propagation in E. coli, 
an AMb1 origin of replication for L. lactis, and a chloramphenicol resistance gene cat 
that can be used for selection in both E. coli and L. lactis. The vector also contains the 
endogenous L. lactis two component system nisR and nisK driven by the constitutive nisR 
promoter, with a reporter mCherry under the control of nisA promoter. This circuit turns 
on mCherry expression when L. lactis cells are exposed to nisin (30 ng/ml). To screen for 
a functional CqsS-NisK hybrid receptor, the nisK gene was replaced by one of the hybrid 
receptor variant genes, which were fused and amplified by overlapping PCR from 
templates in the genomic DNA of V. cholerae (cqsS) and L. lactis NZ9000 (nisK). The 
RBS of the hybrid receptor gene was designed to contain four randomized nucleotides, 
NNNNGG, by the RBS Calculator algorithm (Espah Borujeni, Channarasappa, & Salis, 
2014; Salis, Mirsky, & Voigt, 2009) and covers a predicted range of 3-103 translation 
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initiation rates (Figure 14b). The hybrid receptor plasmid library was screened by picking 
individual colonies into GM17 media with chloramphenicol on a 96-well plate, and co-
culturing the clones with V. cholerae wild type or ∆cqsA mutant. L. lactis and V. cholerae 
co-cultures were assayed on a BD LSRFortessa flow cytometer with a high throughput 
sampler. The clone that showed a difference in the fluorescent output between the two 
co-cultures was propagated for plasmid extraction. The L. lactis plasmid extraction 
followed Qiagen miniprep kit instructions, with an 
extra lysozyme (2 mg/ml in P1 buffer) digestion step 
at 37°C for 10min before lysing the cells. The 
isolated plasmid with the functional hybrid receptor 
was cloned back into E. coli for sequence verification 
and future cloning purpose. 
 
Figure 13. Illustration of plasmid map. 
The final cholera-sensing circuit has a tetR gene incorporated and driven by the 
nisA promoter, whereas the mCherry gene was placed after the TetR-regulated xyltet 
promoter. To maximize the dynamic range of mCherry expression upon CAI-1 activation, 
tetR expression was screened over a randomized RBS library (NNGNNG) of 10–104 
TIRs. The individual colonies from the library cloning were cultured, induced by co-
culturing with V. cholerae, and assayed by flow cytometry. Clones with the highest folds 
of activation were isolated, propagated and sequenced. To provide a colorimetric readout, 
the output mCherry gene was replaced by b-lactamase gene bla, codon optimized for L. 
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lactis and fused to the L. lactis signal peptide usp45 to enable secretion to the 
extracellular environment. 
Hybrid Receptor Design 
BLASTp (Altschul, Gish, Miller, Myers, & Lipman, 1990), UniProt (The UniProt 
Consortium, 2015) and TMpred (Hofmann & Stoffel, 1993) were used to identify domain 
boundaries for the transmembrane and signal transduction domains of CqsS and NisK. 
With reference to previous work on chimeric bacterial receptors (Levskaya et al., 2005; 
Möglich et al., 2008), ten different fusion sequences were designed (Figure 14a). Each 
hybrid receptor variant was screened over an RBS library as described in the previous 
section. To provide structural diversity in the junction between the fused domains, 
randomized nucleotides (up to 6 Ns), were introduced at the junction of the hybrid 
receptor variants for further screening. The E182G mutation found in the functional 
hybrid receptor was outside of the target region for this randomization and thus is not 
considered to be result of the mutagenesis effort. 
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Figure 14. Hybrid receptor design and screening. 
(a) Fusion strategies of the 10 hybrid receptor variants. Amino acid numbers at fusion sites indicate 
positions in the original CqsS and NisK receptor sequences, respectively. (b) RBS library of hybrid 
receptors. The predicted translation initiation rates (TIR) of the randomized RBS library NNNNGG 
(RBS Calculator) cover three orders of magnitude. (c) Hybrid receptor screening with L. lactis-V. 
cholerae co-culture found a mutant of Hybrid Receptor 4 (E182G) that repressed the output gene by 
more than one order of magnitude. Hybrid Receptors 7 and 8 activate gene expression in response to 
CAI-1, but only by a small fractional increase due to high basal expression levels. 
 
Flow cytometry 
BD LSRFortessa cell analyzer (BD Biosciences) with a high throughput sampler 
was used to measure the fluorescent output in L. lactis during hybrid receptor screening, 
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and BD FACSAria II (BD Biosciences) was used for the fluorescent output time course 
measurement. Cell cultures were sampled and diluted 40–100 times in PBS, depending 
on cell density, for flow cytometry analysis. Each sample had at least 10,000 events 
collected, and was analyzed with FlowJo (Flowjo, LLC). For L-V co-culture, the GFP-
integrated L. lactis strain carrying the cholera-sensing circuit was used, and the 
population was gated by GFP+ to obtain mCherry expression levels in L. lactis. 
Beta-lactamase assays 
Nitrocefin (BioVision) was dissolved in DMSO to make a 1 mM stock. It was 
added to samples (bacterial culture supernatant or fecal samples in PBS) in a clear-
bottom 96-well plate to a final concentration of 0.1 mM. For bacterial culture supernatant, 
the plate was placed in a spectrophotometer SpectraMaX M5 (Molecular Devices) to read 
absorbance at 486 nm for 1 hour. For fecal samples, the plate was incubated statically at 
room temperature overnight, and the liquid in each well was transferred to a new plate for 
absorbance measurement. 
Mouse fecal sample collection 
Mice were inoculated with V. cholerae and L. lactis CSL as described in the 
previous chapter, returned to the dam for 10 hours, and fed with a second dose of L. lactis 
CSL. Then the mice were kept in a cotton-padded container at 30 °C for up to 12 hours to 
collect their fecal samples. After collection, fecal samples were dropped in 90 µl of PBS 
in a 96-well plate for  b-lactamase assay with 0.1 µM of nitrocefin. 
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CHAPTER FOUR: THERAPEUTIC PEPTIDE DELIVERY 
4.1 Introduction 
4.1.1 Therapeutic Peptides 
Bioactive peptides are promising therapeutics that are still underexplored. Currently 
in the market, over 90 percent of drugs are made of small molecules coming from 
conventional chemical synthesis (Bayer, n.d.). However, increasing effort has been put 
into the development of a new class of pharmaceuticals, namely biologics, which are 
mostly protein-based therapeutics that mimic native biological functions. Among those 
are the antibodies used for cancer immunotherapies. Apart from large proteins, there are 
also smaller peptides (<50 amino acids) that are also commonly found in physiological 
processes. The majority of signaling molecules in the human body are peptides, including 
hormones, neurotransmitters, growth factors, etc. There are more than 30 identified 
peptide factors just in the gastrointestinal tract (The Medical Biochemistry Page, n.d.).  
Therapeutic peptides can have very diverse functions and applications. Currently 
available peptide-based drugs and the ones under development are mostly targeting 
metabolic diseases and oncology, and there is a trend towards applications in infectious 
diseases and inflammation (Fosgerau & Hoffmann, 2015). These bioactive peptides are 
often discovered from biological hosts like mammal intestines, marine animals, insects, 
plants and microbes. The first blockbuster drug in this category is the glucagon-like 
peptide-1 (GLP-1) which treats type 2 diabetes mellitus. Another successfully 
commercialized peptide therapeutic is the Teriparatide, a synthetic polypeptide fragment 
of the parathyroid hormone used to promote bone formation (Pillay et al., 2012). Other 
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examples of protein and peptide-based drugs serve different functions such as anti-cancer, 
anti-inflammation, anti-microbial are summarized in Figure 15. 
 
Figure 15. Four major areas of application of protein/peptide-based therapeutics and a few 
examples. 
Current protein and peptide-based drugs are mainly for metabolic diseases or tumor treatment, with 
increasing interest and development efforts in the anti-infection and anti-inflammation areas (Cicero, 
Fogacci, & Colletti, 2017; Fosgerau & Hoffmann, 2015; Gaspar, Veiga, & Castanho, 2013; Koetting, 
Guido, Gupta, Zhang, & Peppas, 2016; Pillay et al., 2012). 
 
One big advantage of these bioactive peptides is that they could be indirectly mined 
through the encoding DNA sequences, which makes their discovery significantly 
empowered by bioinformatics advancement (Craik, Fairlie, Liras, & Price, 2013). These 
bioactive peptides are often more specific than small molecules, thus have less toxicity 
and fewer side effects. They are biologically degradable and will not accumulate in 
tissues (Fosgerau & Hoffmann, 2015; Marqus, Pirogova, & Piva, 2017) However, this 
also composes a major disadvantage of therapeutic peptides: the poor stability in plasma 
and digestive tract. Biostability in the GI tract is the reason why in the past century drug 
development had been focused on small molecules less than 500 Da (Craik et al., 2013). 
As a result, out of the very few peptide-based drugs 75% are delivered through direct 
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injections (Fosgerau & Hoffmann, 2015), and therefore their applications are limited to 
systematic use. How to deliver the peptides to the disease site at an effective 
concentration and in a noninvasive manner is an active area of research. 
4.1.2 Oral Delivery of Therapeutic Peptides 
Currently 75% of peptide therapeutics are administered through injection. However, 
non-invasive alternatives are more attractive because of their convenience and user 
friendliness, for instance oral, transdermal and nasal routes. Here we focus on the oral 
route, because it’s the most convenient and widely accepted form of administration and is 
strongly preferred due to the highest level of patient compliance (Craik et al., 2013). 
For oral administration to be effective, three major challenges exist: the first being 
the proteolytic enzymes in the intestinal tract, the second being the movement through the 
mucus layers lining the intestinal walls, and the third being absorption through the 
intestinal walls (Pillay et al., 2012). There are many research efforts trying to address 
these challenges. For the absorption problem, there are molecular permeation enhancers 
that loosen tight junctions at the intestinal epithelial cells and allow more efficient 
paracellular transport, for example oleic acid, EDTA, occludin peptide, and Chitosan. For 
the biostability challenge in the upper GI tract, a few proposed methods include co-
administration with protease inhibitors, encapsulation by nanoparticles or microparticles, 
conjugation with poly(ethylene glycol), introduction of D-animo acids, and coating with 
stimuli-responsive hydrogels that may also have mucoadhesive properties (e.g. thiolated 
polymers) (Choonara et al., 2014; Pillay et al., 2012).  
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While the above-mentioned chemical modifications of therapeutic peptides are 
promising directions of drug development, they will incur additional manufacturing cost, 
and the modifications may also affect the bioactivity of the drugs.  As an alternative, 
biotechnology offers a new way that could potentially reduce the chemical manufacturing 
cost significantly and deliver the therapeutics efficiently. That is to use recombinant 
microbial factories. There have been various efforts exploring the benefits and potential 
novel functions that engineered bacteria can bring to the medical world. Some examples 
include surface display of antigens to provide mucosal deliverable vaccines, surface 
display of antibodies to function as anti-infectives, and production and secretion of 
therapeutics molecules to treat inflammations or to prevent allergy (Piñero-Lambea et al., 
2015; Wells & Mercenier, 2008; Young et al., 2011). There are a few advantages 
associated with microbial delivery of therapeutics: (1) the cell wall and membrane 
provide a good protection against enzymatic degradation passing through the GI tract; (2) 
the possibility of the host microbe colonizing the gut and producing the therapeutics 
continuously over a long term; (3) potential novel features to be added to the host cells by 
genetic engineering. Most interest in microbial therapeutic delivery has been in lactic 
acid bacteria, due to their safety profile and high survival rate through the gastric 
environment (Wells & Mercenier, 2008). One good example is the study using 
engineered L. lactis which produces the anti-inflammatory cytokine IL-10 in the gut to 
treat colitis (Braat et al., 2006; Lothar Steidler et al., 2000). Another example of 
microbial delivery of therapeutic peptides used Lactobacillus gasseri to produce GLP-1 
(1-37) to alleviate type 2 diabetes in rats (F. F. Duan et al., 2015). 
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Functional molecule type Model of study Applications 
DNA Tissue culture; Mouse Vaccines 
Peptides Mouse HIV-1, fusion inhibitors; colitis, trefoil peptides 
ScFvs Mouse Anti-infectives 
Antigens Mouse; Chicken Vaccines 
Allergens Mouse Prevention of allergy 
Cytokines Mouse; Human Inflammatory bowel disease and colitis, vaccine adjuvants 
Enzymes Mouse Therapy for colitis and enzyme deficiencies 
Table 2. Summary of medical applications that lactic acid bacteria have been used for as 
delivery vehicles (adapted from Wells & Mercenier, 2008). 
 In spite of the great interest and potential in microbial delivery systems, there are 
still tremendous obstacles in achieving practical applications. Here in this chapter, I aim 
to improve the feasibility of microbial-based therapeutic peptide delivery. I demonstrate a 
few of the challenges using lactic acid bacteria to deliver peptide therapeutics, including 
intracellular peptide stability, peptide structure and secretion efficiencies, and my strategy 
to overcome these challenges.  
4.2 Results 
4.2.1 Peptide Selection 
With the initial aim to produce a therapeutic module that targets the V. cholerae 
pathogen in the gut, I screened 20 antimicrobial peptides (AMPs) that were reported to 
have greater potency against Gram-negative bacteria (Table 3). The candidates were 
limited to short linear peptides with minimal secondary structures and no post-
translational modifications, to ensure proper production by the bacterial host. These 
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peptides were chemically synthesized by the external vendor LifeTein and tested against 
Gram-positive and Gram-negative bacteria. Among those screened, AMP9 (Cecropin B) 
and AMP10 (Cecropin P1) were verified to have inhibitory effect against V. cholerae, but 
not the host bacteria L. lactis. In addition, AMP3, AMP4 and AMP15 exhibited strong 
potency in killing both Gram-positive and Gram-negative bacteria (Figure 16). With the 
help from our collaborator, we also obtained some data on the bioactivity of these AMPs 
on the native microbiome, as an evaluation of their off-target killing, or their potential to 
modify the microbiome (Table 4). Based on these data, we selected five AMPs to test: 
AMP3, AMP4, AMP9, AMP10 and AMP15. 
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# NAME	   AA Sequence 
1 	  	   KKWRWWLKALAKK  
2 	  	   LIAGLAANFLPKLFCKITK  
3 	  	   WKLFKKILKVL  
4 	  	   KWKLFKKIGAVLKVL  
5 	  	   TAKPEGLSY  
6 	  	   APVPFSCTRGCLTHLV  
7 	  	   ACQCPDAISGWTHTDYQCHGLENKMYRHVYAICMNGTQVYCRTEWGSSC  
8 BP100 KKLFKKILKYL  
9 Cecropin B KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL  
10 Cecropin P1 SWLSKTAKKLENSAKKRISEGIAIAIQGGPR  
11 A3APO	   RPDKPRPYLPRPRPPRPVR  
12 Alyteserin	   GLKDIFKAGLGSLVKGIAAHVAN    
13 Lse-Cec1 GWLKKIGKKIERVGQHTRDATIQTIGVAQQAANVAATLKG  
14 Dermaseptin-L1 GLWSKIKEAAKAAGKAALNAVTGLVNQGDQPS  
15 Adepantin-1 GIGKHVGKALKGLKGLLKGLGES  
16 Bac 5 (1-23) RFRPPIRRPPIRPPFYPPFRPPIRPPIFPPIRPPFRPPLGPFP  
17 Bac 7 (1-35) RRIRPRPPRLPRPRPRPLPFPRPGPRPIPRPLPFPRPGPRPIPRPLPFPRPGPRPIPRPL  
18 Apidaecin IB GNNRPVYIPQPRPPHPRL  
19 PR-39	   RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFP  
20 Magainin I GIGKFLHSAGKFGKAFVGEIMKS  
Table 3. List of screened antimicrobial peptides.  
(Casteels, Ampe, Jacobs, Vaeck, & Tempst, 1989; Conlona et al., 2007; Gennaro, Skerlavaj, & Romeo, 
1989; Jureti, Vukičevi, Ili, Antcheva, & Tossi, 2009; Long et al., 2005; Mardirossian et al., 2014; 
Pöppel, Vogel, Wiesner, & Vilcinskas, 2015; Santamaria et al., 2005; Scocchi, Tossi, & Gennaro, 
2011; G. Wang, Li, & Wang, 2016) 
 
 
Figure 16. Selected AMP activity screening on V. cholerae and L. lactis. 
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AMP conc: 100ug/ml
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Table 4. AMP bioactivity screening over representative microbiome species.  
Numbers are minimal inhibitory concentrations (MICs) in µM. Legends to species abbreviations 
(Gram): Am, Akkermansia muciniphila (-); Bt, Bacteroides thetaiotaomicron (-); Bf, Bacteroides 
fragilis (-); Bo, Bacteroides ovatus (-); Bv, Bacteroides vulgatus (-); Bu, Bacteroides uniformis (-); Be, 
Bacteroides eggerthii (-); Pd, Parabacteroides distasonis (-); Pc, Prevotella copri (-); Ca, Collinsella 
aerofaciens (+); Ro, Ruminococcus obeum (+); Rt, Ruminococcus torques (+); Csc, Clostridium 
scindens (+); Csy, Clostridium symbiosum (+); Csp, Clostridium spiroforme (+); Er, Eubacterium 
rectale (+). 
4.2.2 Peptide Secretion by L. lactis 
The next step was to test the ability of L. lactis to secrete the chosen AMPs. We 
tried to utilize the sec-dependent pathway (Beckwith, 2013) of L. lactis to secrete the 
peptides directly. This was done by adding the secretion signal peptide usp45  to the N-
termini of the peptides (Morello et al., 2007; Poquet, Ehrlich, & Gruss, 1998). However, 
we encountered a few obstacles with the attempt. First of all, the peptides were not able 
to translocate the membrane during secretion (Figure 17). This may be due to the 
enrichment of positive charge over the N-terminal of the peptides, which is a structural 
signature of most linear AMPs (Brogden, 2005). This is evidence that the sec-pathway 
machinery is more sensitive to substrate’s structure than size (Sophie Drouault, Corthier, 
Ehrlich, & Renault, 2000). When we compared the charge distribution (Bleasby, 2001) of 
three non-secreted peptides (AMPs4, 9 and 10) to three reported secreted peptides (Le 
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Loir et al., 2005; Martín et al., 2007; Martínez, Kok, Sanders, & Hernández, 2000), it was 
clear that the non-secreted peptides all displayed a higher total positive charge and more 
extensive distribution within the first 10 amino acids at the N-termini (Figure 18). This 
was further verified when we placed a spacer sequence “LEISS” between the signal 
peptide and the AMPs, which was shown to enhance secretion of most protein substrates, 
the AMPs could be translocated effectively (Figure 17). This enhancer sequence can 
provide a shielding effect to the positive charge on the peptides. However, the functions 
of most therapeutic peptides are almost exclusively determined by the charge and the 
three-dimensional structure of the peptides, which makes them extremely prone to any 
sequence modifications (Pillay et al., 2012). Therefore, it was not a surprise that with the 
“LEISS” modification at the N-termini, the AMPs all lost their bioactivity (data not 
shown).  
 
 
Figure 17. Western blots of VSV-G tagged antimicrobial peptides in cell pellet fraction and 
supernatant. 
AMPs are not efficiently secreted by L. lactis. A “LEISS” sequence between the signal peptide usp45 
and AMPs enables more efficient secretion, but disables AMPs’ inhibitory effects. 
 
1 | 2 |  3 |  4 | 5 |  6 | 7 | 8 |          |9|10|11|12|13|14| 1/2: usp45-NucA 
3/4: usp45-LEISS-NucA 
5/6: usp45-AMP10 
7/8: usp45-AMP9 
9/10: usp45-AMP9 
11/12: usp45-LEISS-amp9 
13/14: usp45-LEISS-AMP10 
Each pair of lanes has cell pellet 
fraction on the left and 
supernatant on the right. 
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Figure 18. Charge distribution of three representative peptides that are secreted versus three 
non- secreted by L. lactis. 
Non-secreted peptides have higher total charge number and more extended charge distributions over 
first ten amino acids from N-termini. 
 
 
In summary, the innate structure of the AMPs prevents efficient secretion from L. 
lactis through the sec-dependent pathway. Addition of a capping sequence that shields 
the positive charge enables secretion but disables the antimicrobial bioactivity of the 
peptides. This dilemma imposes a major obstacle in utilizing L. lactis secretion as a direct 
method of peptide delivery. 
4.2.3 Intracellular Stability of Short Peptides in L. lactis 
To bypass the secretion problem, we attempted another delivery scheme: the load-
and-burst model. This method aims to preload the cells with active peptides in the cytosol. 
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Upon trigger by a targeted signal (e.g., a pathogen), the cells auto-lyse through the 
expression of holin and lysin and release the intracellular cargos (Sanders, Venema, & 
Kok, 1997). When a peptide is to be synthesized directly by ribosome (with no N-
terminal modifications or signal peptide), there will be an inevitable methionine added to 
the N-terminus of the peptide (M-AMP). To ensure the bioactivity of the M-AMPs, we 
synthesized the AMP9 and AMP10 with additional N-terminal methionines and tested 
them on bacteria. They proved to be still active, with M-AMP9 displaying an even 
stronger inhibitory effect than the original peptide (Table 4).  
Figure 19. AMP intracellular stability testing with Western blotting and AMP-mCherry fusion 
proteins. 
(a) Western blotting result suggests AMP9, when constitutively expressed without any modifications, 
is not stable in the cytosol. However, it can be stabilized with the usp45 secretion tag at the N-
terminus. (b) Flow cytometry fluorescence readout of AMP-mCherry fusions indicates that AMP3 and 
AMP9 destablize C-terminal fusion proteins. In contrast, AMP4, 10 and 15 can be stabilized by C-
terminal fusions. (c) Corresponding Western blot of AMP-mCherry fusion. Lane labels in order from 
left to right: mCherry, AMP3/4/9/10/15-mCherry fusion, usp-AMP10-mCherry, usp-AMP10, usp-
NucA.    
 
Next, we evaluated the intracellular stability of the peptides. Initial Western blot of 
AMP9 indicated that the standalone peptide was not well maintained inside the cell. In 
order to have a faster method of screening, we constructed AMP-mCherry fusion proteins, 
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and assessed the proteins’ stability by reading the fluorescent signals on a flow cytometer. 
However, the stability of the fusion protein was not fully predictive of the stability of the 
bare peptide. All five AMPs turned out to be unstable when evaluated by Western 
blotting (data not shown). This is consistent with AMP3 and AMP9-mCherry fusions, 
whereas AMP4 and AMP10 were in fact stabilized by the C-terminal fusion of mCherry 
(Figure 19). On the other hand, a surprising finding was that the secretion tag usp45 had 
the extra function of stabilizing the peptides (Figure 19), which was probably due to the 
chaperon activity of SecB in the sec pathway. 
To overcome the stability issue, we obtained two peptidase knockout strains from 
Dr. Jan Kok at the University of Groningen in the Netherlands (I Mierau et al., 1996). L. 
lactis houses a consortium of peptide importers and peptidases as it evolved the 
exceptional ability to grow on milk (Christensen, Dudley, Pederson, & Steele, 1999). We 
expected the mutants that had deficient peptidase abilities might exert slower 
degradations of the exogenous peptides. The ∆pepCN strain is a mutant lacking two 
major general aminopeptidases, and the ∆pepXTOCN strain has three additional 
peptidases knocked out, including an endopeptidase, a tripeptidase and a prolyl dipeptidyl 
aminopeptidase (Savijoki, Ingmer, & Varmanen, 2006). Despite having significantly 
reduced growth rate in milk (I Mierau et al., 1996), neither mutant showed better 
maintenance of the AMPs in the cytosol. Although the ∆pepCN strain has enhanced 
expression of the AMP-mCherry fusions, the bare peptides were still degraded quickly 
(Figure 20).  
 
	  	  
55 
     
Figure 20. Peptidase mutants of L. lactis, ∆pepCN and ∆pepXTOCN, do not enhance intracellular 
stability of peptides. 
Left: Fluorescence readout of AMP-mCherry fusions, with increased stability for AMP4- and AMP15-
mCherry fusions in ∆pepCN only. Right: Western blotting of induced AMP expression in wildtype 
versus ∆pepCN mutant. Each AMP construct has two lanes: wildtype expression on the left, ∆pepCN 
expression on the right. 
 
In conclusion, intracellular maintenance of short peptides by L. lactis is a 
significant issue that precludes the use of the “load-and-burst” method of delivery. N-
terminal sequence may be important in signaling protein degradation (the “N-end rule” 
(Varshavsky, 1996)), which results in fast degradation of AMP3- and AMP9-mCherry 
fusion proteins. The length of the peptide may also play a role in determining its stability, 
as demonstrated by AMPs 4, 10 and 15, which can be stabilized by C-terminal fusion 
with mCherry. L. lactis is known to house a consortium of proteinases and peptidases to 
facilitate metabolism on casein. A knockout of a few key peptidases does not help in 
stabilizing the AMPs in the cytosol. Even though the mutants display growth defects on 
milk, this collection of knockouts may not cover all the peptide degradation machinery in 
L. lactis.  
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4.2.4 Carrier-protein-assisted Secretion and Protease Activation of Peptides 
Learnt from the lessons of the first two peptide delivery strategies, we propose 
another possible scheme that utilizes a two-cell system: a producer-cell that secretes pro-
peptides that are not functional, and an activator-cell that displays proteases that cleave 
the pro-peptides, creating an active therapeutic (Figure 21). On the producer cell, we 
utilized the ready-built secretion cassette — the signal peptide usp45, the secretion 
enhancer “LEISS”, an optional carrier protein, followed by a specific protease cleavage 
sequence and the therapeutic peptide. The activator cells display proteases on the surface 
and desirably colonize at specific regions of the GI tract, for instance Lactobacillus spp. 
at the small intestines, and E. coli in the colon. Once the pro-peptides are produced and 
released in the target region, the proteases on the surface of activator cells recognize the 
cleavage sequence, digest the pro-peptides and liberate the active therapeutic peptides.  
  
Figure 21. The producer-activator system for therapeutic peptide delivery. 
SP, signal peptide. SE, secretion enhancer sequence. Cut, protease cleavage site. TP, therapeutic peptide. 
Green shapes, protease displayed on cell surface. By utilizing different species as activator cells that 
colonize specific regions in the intestines, it is possible to direct the therapeutics to the target region.  
 
The key to this system is to identify a working protease that cleaves at the C-
terminus after a consensus sequence and can tolerate different amino acid residues at the 
P1’ position (1st amino acid on the N-terminus of the cleavage site). A few commonly 
Producer Activator Target Region 
L. lactis Lactobacillus spp. Small intestines 
L. lactis E. coli Colon 
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used tag-removing proteases, Tev protease, Factor Xa and enteropeptidase, are good 
candidates (PeptideCutter, n.d.). Although TEV protease has a preference for glycine at 
P1’ position, there has been evidence that it can tolerate a few other amino acids 
(unpublished data). In addition, two other candidates are the SplB protease from 
Staphylococcus aureus (Pustelny et al., 2014), and Granzyme B from human cytotoxic 
lymphocytes (Thornberry et al., 1997). Table 5 summarizes the candidate proteases, their 
cleavage sequences, origins, native functions, and structures. These factors may influence 
the functionality of the protease when produced heterologously and displayed on a 
bacteria surface. These proteases were cloned into three different surface display 
cassettes: fusion to the ice nucleation protein (INP) N-terminus in E. coli (Li, Gyun Kang, 
& Joon Cha, 2004), the Sortase A crosslinking consensus LPXTG in L. lactis (Dieye et 
al., 2010), and C-terminal fusion to the membrane protein PgsA in Lactobacillus (Narita 
et al., 2006).  
Protease Cleavage consensus Origin Function Structure 
TEV Protease ENLYFQ ↓ G tobacco etch virus activate viral proteins 243aa single chain 
SplB WELQ ↓ X Staphylococcus aureus 
modulate physiology 
and virulence 204aa single chain 
Factor Xa IE/DGR ↓ X human liver activate thrombin (coagulation cascade) 
multi-domain; 
catalytic domain 
254aa 
Enteropeptidase DDDDK ↓ X 
(not P) 
human/bovine 
intestines 
activate trypsin 
(digestive tract) 
multi-domain; 
catalytic domain 
235aa 
Granzyme B IEPD ↓ X human cytotoxic lymphocytes 
activate caspases 
(apoptosis pathway) 
single chain; 2 
disulfide bonds 
Table 5. Candidate proteases with specific cleavage sequences and good flexibility with P1’ residues.  
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To evaluate the activity of the surface-displayed proteases, a few commercial 
proteases were purchased as positive controls, together with testing substrates that are 
fluorogenic when cleaved (except for SplB substrate, which is not available 
commercially). A serial dilution of the control protease was produced for each protease, 
and mixed with the corresponding test substrate, which generates a standard curve. The 
proteases produced by the following conditions were then tested on the substrate: (1) 
secreted from in L. lactis supernatant; (2) surface-displayed on E. coli MG1655; (3) 
surface-displayed on E. coli Nissle 1917; (4) surface-displayed on L. lactis. The 
fluorescence generated by the test protease was then fit onto the standard curve to 
measure its activity. Results are shown in Figure 22. TEV protease displayed on E. coli, 
or secreted by L. lactis, displayed measurable activity. Granzyme B displayed on E. coli 
or L. lactis also showed some activity on the substrate. However, it was inconclusive 
whether the secreted form was also active, because the supernatant had too high an 
autofluorescence that interferes with the substrate reading. In contrast, enteropeptidase 
and factor Xa did not show any activity in each of the engineered forms. This might be 
due to the relatively more complicated structure of these two human-source proteases. 
Only the active domains were expressed in bacteria, which may be not sufficient to 
conserve their activities. Since enteropeptidase is produced in the upper small intestines, 
it is possible to utilize the native enteropeptidase activity to cleave the pro-peptide. 
However, this will restrict the location of activation to upper small intestine. The single-
chained TEV protease and Granzyme B were easier to produce by bacteria and still 
displayed activities. Although we did not have fluorogenic substrate to test the SplB 
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protease, based on these results, it is very likely that the bacteria-originated single-
chained protease should be functional when expressed by these methods.  
 
Figure 22. Protease activity assay results for TEV protease, Granzyme B, Enteropeptidase and 
Factor Xa, on each corresponding fluorimetric substrate. 
Standard curves are defined by the activity of serial dilutions of control proteases, with the 
corresponding wildtype background. Each data point is an average of duplicates. SP, supernatant of L. 
lactis; MG1655 and Nissle, E. coli surface display in each corresponding strain; L. lactis, surface 
display on L. lactis. Each data point of tested samples is the average of three replicates. 
 
On the pro-peptide, the optional carrier protein can bring the benefits of robust 
secretion and better stability, as well as a more convenient method of secretion assay than 
Western blotting. Here we used the well-characterized NucA from Staphylococcus 
aureus as a carrier. Together with the secretion signal peptide usp45 and the enhancer 
sequence “LEISS”, NucA protein is secreted efficiently (Figure 23). It also offered a 
convenient metachromatic assay (the Toluidine Blue DNA-Agar assay (F Lachica, 
Hoeprich, & Franti, 1972)) to verify secretion and gives a semi-quantitative measure of 
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the pro-peptide concentration in the supernatant (Figure 23).  The therapeutic peptide was 
fused to this functional carrier after a linker sequence and the specific protease cleavage 
sequence.  
 
Figure 23. NucA secretion analysis by Western blotting and the Toluidine Blue DNA-Agar assay. 
To test peptide activation, the supernatant containing secreted NucA-AMP4 fusion 
proteins was concentrated ten times by Amicon centrifuge columns (UFC500324), 
washed with protease reaction buffer, and then incubated with control protease (TEV and 
SplB proteases tested). After 2 or 16 hours of incubation, the condensed supernatant was 
mixed 1:1 with E. coli culture of OD600 0.1. However, we observed no growth inhibition 
by the digested peptides. Further investigations could be done to find out whether the 
issue is due to inefficient peptide digestion, or sub-inhibitory concentrations of the 
digested peptide. Western blotting can help visualize whether the fusion proteins were 
effectively digested by protease. If digestion is not an issue, we could try a higher 
concentration factor for the supernatant processing, to test if increased concentration of 
the peptides could show antimicrobial activities.  
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4.3 Conclusion 
The probiotic bacterium L. lactis also possess a potential to function as a 
therapeutics delivery vehicle. There has been notable effort to engineer surface antigen 
displays on L. lactis to facilitate mucosal delivery of vaccines. Here I propose to utilize 
this bacterium for a wider application of therapeutic peptide delivery to the GI tract. 
Peptide therapeutics can have a wide variety of applications, including anti-inflammation, 
anti-infection, and metabolic regulations. Because L. lactis is highly tolerant to gastric 
acid and is metabolically active throughout the GI tract, it can function as a microbial 
factory to produce and dispense protein or peptide-based therapeutics in situ. This feature 
overcomes the stability challenge that the digestive tract imposes to protein and peptide-
based drugs.  
 However, it is not straightforward to engineer L. lactis to produce and release 
therapeutic peptides. Although it has been used significantly for heterologous protein 
expression and secretion, L. lactis does not maintain short peptides stably in the cytosol, 
nor is the sec-dependent pathway robust for short peptide secretion. The highly variable 
and stringent structural requirement of therapeutic peptides make the direct secretion 
method invalid, and the “load-and-burst” model is not feasible either due to the poor 
stability of intracellular peptides.  
To overcome all these obstacles, I propose a producer-and-activator pair of cells for 
peptide delivery. In this system, a transiting species of bacteria, like L. lactis, 
constitutively produces a pro-peptide that has a carrier protein and a capping sequence to 
enhance secretion and stabilize the therapeutic peptide. However, this pro-peptide is not 
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active, until it encounters an activator cell, which displays a protease that can specifically 
cleave off the therapeutic peptide thus activating it. The activator cells will be colonizing 
species that are present only in specific regions of the intestines, which further enables 
targeted delivery of the drugs. We have successfully displayed and verified the activity of 
at least two types of proteases, the TEV protease and Granzyme B, with another 
promising candidate SplB. We will further test the pro-peptide constructs and verify their 
activity after protease digestion. Eventually, we will test the producer-activator pairs in 
vitro and in mouse models of enteric infections. 
4.4 Methods 
Cloning 
Bacterial strains used in this part are: E. coli MG1655, E. coli Nissle 1917, L. lactis 
MG1363, L. lactis MG1363 ∆pepCN and ∆pepXTOCN. Lactobacillus gasseri 
ATCC33323 and Lactobacillus plantarum were also used, but no positive colonies were 
obtained due to low transformation efficiencies. Specific methods and plasmid backbones 
are similar to previous methods described in Chapter 2 and 3. Constitutive expressions 
are all driven by the xyltet promoter, both in E. coli and L. lactis. 
Protease sequences were obtained from Uniprot (The UniProt Consortium, 2015) 
and codon optimized for L. lactis by IDT web tool. Specific mutations and modifications 
were introduced. TEV protease was mutated at S219V, to abolish self-cleavage and 
inactivation (Kapust et al., 2001). SplB protease and Granzyme B sequences were taken 
without the original signal peptides (Residues 1-36 in SplB, 1-20 in Granzyme B). The 
enteropeptidase sequences of bovine and human both only included the catalytic domain 
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of the light chains. For Factor Xa, only the active heavy chain sequence was cloned.  
The surface display cassettes were synthesized as gene fragments by IDT and fused 
with protease genes by overlapping PCR. For E. coli display, the N-terminus (1-179) of 
ice nucleation protein was used (Li et al., 2004). For L. lactic display, the Sortase A 
consensus LPXTG followed by the C-terminus of the surface protein PrtP (last 36 
residues) was used. The proposed surface display in Lactobacillus spp. follows a whole 
protein fusion to the B. subtilus transmembrane protein PgsA (Narita et al., 2006). pgsA 
gene was amplified from B. subtilus genome, and fused to each protease gene by 
overlapping PCR. However, due to low transformation efficiency, we were not able to 
obtain a positive strain of Lactobacillus with the surface display cassette.  
Secreted constructs, including the bare AMPs, AMP with a carrier protein, and 
secreted proteases, were all headed by the usp45 signal peptide towards the sec-
dependent pathway (Beckwith, 2013; Borrero et al., 2011). When necessary, the construct 
may contain a vsv-G tag for Western blotting.   
Western Blot 
The Western blot protocol for L. lactis was adapted from Le Loir et al. 1998.  
Briefly, 1 ml of the supernatant of the culture is precipitated with 10% 
trichloroacetic acid (TCA) at 4 °C for over 4 hours. The precipitated protein is then 
pelleted and washed with 1 ml of acetone. After spinning and removing acetone, the 
protein is dissolved in 25 µl of 50 mM sodium hydroxide and mixed with 25 µl of the 2x 
loading buffer. For the cell pellet, it was treated with 10% TCA similar to the supernatant. 
After acetone wash, the pellet is resuspended in 85 µl TES buffer with 10 mg/ml 
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lysozyme and incubated at 37 °C for 30 min. Then 20 µl of 10% SDS is added to lyse the 
cells, and it is then mixed with 120 µl of the 2x loading buffer. Both the supernatant and 
the cell pellet fractions are boiled at 95 °C for 10 min before loading to the gel.  
The processed samples are then loaded to the 4–20% Mini-PROTEAN TGX precast 
gel (Bio-rad) and run at 120 V until the dye is reaching the bottom. The gel is then 
transferred to nitrocellulose membrane with a semi-dry transfer kit. The transfer runs at 
10 V for 30 min with Tris-glycine buffer (Bio-rad 1610771) and 20% methanol. The 
resulting membrane is then blocked by 3% w/v milk (Criterion C6961) in TBS buffer 
with 0.05% Tween 20 (TBST). Primary antibody (mouse anti-vsv-G antibody, ab50549 
Abcam) at 1:10,000 dilution in TBST+3% milk replaces the blocking buffer and 
incubation at room temperature goes for 3 hours. Alternatively, primary antibody 
incubation can be done at 4 °C overnight. Then the membrane is washed three times with 
TBST, and incubated for 1 hour with secondary antibody (anti-mouse IgG conjugated 
with Alexa Fluor 488, #4408 by Cell Signaling Technologies) at 1:10,000 dilution in 
TBST+3% milk. After three times of wash with TBST, the membrane is imaged at 
ex490/em525 nm. 
Toluidine Blue DNA-Agar NucA Assay 
DNA-Agar with Toluidine Blue was made with the Sigma D2560 DNase Test Agar 
Mix following the instructions. Wells were punched on the agar pad with a 1 ml pipette 
tip. 10 µl of the test supernatant was dispensed in a well. The agar plate with test 
supernatant was then incubated at 30 °C for 1–3 hours. For more obvious halos, incubate 
the assays overnight. 
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Protease Assays 
Protease activities were tested with commercial assay kits and benchmarked with 
gradients of control proteases. Supplier of each is listed in Table 6. 
Protease Control Assay Kit Substrate Conjugate Fluorescence (ex/em) 
TEV AcTEV (Invitrogen) 
SensoLyte 520 
(Anaspec) 
5-FAM dye and QXL 520 
quencher 490nm/520nm 
Factor Xa (with kit) SensoLyte 520 (Anaspec) 
5-FAM dye and QXL 520 
quencher 490nm/520nm 
Granzyme B (with kit) BioVision K168 
7-Amido-4-
trifluoromethylcoumarin 
(AFC) 
380nm/500nm 
Enteropeptidase 
ProteoSure bovine 
enterokinase 
(Marvelgent) 
Sigma G5261 β-naphthylamide 320nm/420nm 
SplB WELQut (Thermo Fisher) NA NA NA 
Table 6. Protease assay control and substrate list. 
The substrate was mixed 1:1 with control protein of different concentrations, or 
with samples to be tested. Four different forms of proteases were tested: (1) secreted by L. 
lactis; (2) surface display by E. coli MG1655; (3) surface display by E. coli Nissle 1917; 
(4) surface display by L. lactis. Control proteases were prepared at desired concentrations 
and 0, 0.5, 1, 2.5 and 5 µl were added to (1) standard reaction buffer; (2) wildtype L. 
lactis supernatant; (3) wildtype E. coli MG1655; (4) wildtype E. coli Nissle 1917; and (5) 
wildtype L. lactis, to ensure the same background as each type of samples to be tested. 
After mixing the substrate and the protease controls/samples in a 96-well plate, reactions 
were incubated in darkness for 1 hour before taking the fluorescence readings.  
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Figure 24. Protease activity assay layout on a micro-well plate. 
Fusion Protein Cleavage and AMP Activity Testing 
L. lactis culture supernatant containing secreted carrier-AMP fusion proteins was 
concentrated by the Amicon spin columns (Milipore) by ten times. It was then washed 
once with the protease reaction buffer (25mM Tris-HCl buffer at pH 8.0) and recovered 
to desired volume. A 10 µl sample was taken from each to spot on the Toluidine Blue 
DNA-Agar to verify presence of the fusion protein, and the rest of the volume was 
divided into two parts: one for protease digestion and the other as negative control. 0.5 µl 
of commercial protease was added to 100 µl of fusion protein substrate and incubated for 
16 hours at room temperature. Then 100 µl of early log E. coli bacteria (OD600 ~0.1) was 
added to each well of the digested and undigested supernatant. The growth kinetics was 
recorded for 10 hours with a spectrophotometer.  
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CHAPTER FIVE: CONCLUSION AND FUTURE DIRECTIONS 
In this dissertation, I have presented three aspects of exploiting the benefits of 
probiotics for applications in gastrointestinal disease management. First, we discovered 
that a regular dosing of the lactic acid bacterium, L. lactis, can confer a prophylactic 
effect against cholera infection in infant mice. We further demonstrated that this 
prophylactic effect was mainly attributed to lactic acid production by L. lactis. Second, 
we engineered L. lactis to form a biosensor that could detect the specific chemical signal 
of V. cholerae in situ and report the infection through a convenient colorimetric assay 
using a fecal sample. Finally, we proposed a generalizable therapeutic peptide delivery 
system based on genetically engineered L. lactis and commensal bacteria, which could 
overcome the structural restriction on the peptides to be secreted by the microbial host.  
There are many exciting opportunities to be explored beyond this work, including a 
deeper understanding of the microbial ecology and how to apply it towards broader 
realms of disease management, and potentially more sophisticated biosensors to explore 
the GI tract and more versatile response functions. It is important to continue building 
and testing the proposed peptide delivery system in order to obtain a working producer-
activator pair and demonstrate its functionality in one or more animal models with actual 
therapeutic peptides, such as antimicrobial or anti-inflammatory peptides.  
To further study the microbial species interaction and their effects on the ecosystem 
and host health, there are two possible strategies: the top-down method and the bottom-up. 
The top-down method looks at phenotypes of the hosts and aims to identify specific 
species contributing to a desirable trait, whereas the bottom-up strategy begins with in 
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vitro studies of the microbes and tries to project beneficial functions that could translate 
to in vivo. The top-down method will need to leverage large cohort microbiome studies 
and bioinformatics analyses, to search for potential enriched species or strains in groups 
of subjects who display better recovery or stronger resistance to a pathogen or condition. 
When a hit is found, further mechanistic studies will help to establish a better 
understanding of the general rules of the microbial interspecies network and host-microbe 
interactions. With more evidence and understanding, we may be able to actively search 
for and even design novel microbes that can modify the ecosystem towards desired 
outcomes. The bottom-up method, on the other hand, may be more laborious, because of 
the huge number of potential candidate species that would need to be screened. Therefore, 
robotics, automation, and streamlined operations will be necessary to carry out 
comprehensive and systematic screenings for beneficial species. An even bigger 
challenge will be the culturability of many microbial species and discovering the optimal 
screening conditions, which should be a good proxy of the actual gut environment. Taken 
together, the top-down strategy seems to be a more feasible and reliable method with 
current technology.  
Regarding the smart biosensor development, there are also many directions to 
explore. Considering the GI tract alone, there are still many aspects about this 
environment that we do not understand, nor have an effective method to study. Our 
current understanding of the microbiome and the gut environment is largely based on 
fecal sample analyses. Feces can be a good proxy for the gut lumen microbiome in many 
aspects, but it is in fact very different from the microbiota at the mucosa, which is the 
	  	  
69 
other important microbial niche in the gut. Moreover, fecal samples cannot provide 
information about the spatial distribution of the microbiota and the various chemical cues 
in the extended GI tract (Floch, Ringel, & Walker, 2016). In addition, not all microbes in 
the gut, including pathogens, exhibit steady shedding in feces (Kim et al., 2017). With all 
of these black boxes concerning the gut environment, future smart biosensor development 
will face many opportunities and challenges. For example, a potential antibody-based, co-
localization-triggered receptor (similar to the chimeric-antigen receptor in engineered T-
cells) on a microbial surface would enable sensing of many more targets of interest. 
Combined with a long-term recording function (Perli, Cui, & Lu, 2016), the smart 
biosensor would be able to record the various signals of interest it encountered along the 
GI tract in the order that the signals have been encountered. An examiner could then 
extract and analyze samples of the sensors and obtain information about the spatial 
distribution of these targets in the GI tract.  
In summary, there are many exciting opportunities to explore for using microbial 
factories as therapeutic delivery vehicles, gut microbial ecosystem-inspired disease 
management, as well as multi-functional biosensors to enable better understanding and 
disease diagnosis of the GI tract.  
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